 
  Page i 
Version: 1.2, Date: 19OCT2021   
   
 
 
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and  
Efficacy of Antithrombotic  and Additional  Strategies in Hospitalized Adults with COVID -
19 
 
Short Title:  ACTIV -4 ACUTE  (AC-INPT)  
 
ClinicalTrials.gov Number:  [STUDY_ID_REMOVED]  
 
Supported by : 
National Hea rt Lung and Blood Institutes (NHLBI), National Institute of Neurological 
Disorders  (NINDS) , ACTIV (ACTIV IV) , National Institutes of Health  (NIH) , Biomedical 
Advanc ed Research and Development Authority (BARDA) , Operation Warp Speed (OWS), 
U.S. Department of Health & Human Services (HHS)  
 
Version Number: 1.2 
 
OCT 19  2021  
 
  
 
  Page ii 
Version: 1.2, Date: 19OCT2021   
   
 
 
Protocol Revision History:  
 
Version 
Number  Status/Summary of Revisions Made  Version Date 
1.0 Appendix 1 outlined possible example scenarios for adaptive 
design. Arms A and B included.  August 21, 2020  
1.1  Section 5.1 Inclusion Criteria: Broadened type of 
SARSCoV2 tests, in accordance with NIH 
recommendations  
 Appendix 1: Revised to reflect the master protocol current 
state of arms  
 Appendix 1 .1: Adds arm C  
 Appendix 1.2: Adds arm D   
 Appendix 2 : Neuroimaging detailed criteria for hemorrhagic 
stroke conversion removed to be refined in the event 
charter  
 Appendix 2 : The method of calculati on of ventilator -free 
days was removed from the description of the primary 
endpoint, where it is not relevant. The definition will appear 
in a manual . 
 Appendi ces 1 and 3: New exclusion for Arm A for patients 
who require ICU level of care at screening, based on DSMB 
review and NHLBI Determination, as of Dec 19. 2020  
 New exclusion for Arm B for patients who do not require 
ICU level of care at screening, based on DSM B review and 
NHLBI Determination, as of  Jan 21 . 202 1 
 Appendi x 3: Added recommendation to enroll patients with 
elevated d -dimer  
 Appendices 3, 4: Clarified quality of life assessment on 
schedule of assessments  
 Appendix 5: Clarification on blood collection window  
 Appendix 7 Added for arm C  
 Section  13.3.2: Added investigator “designee” to consent 
process  
 Appendix 8: Added for arm D   February 01 , 2021  
1.2  Added additional study personnel to contacts section  
 Study duration changed to approximately 2 years  
 Added p otential follow -up after one year 
 Added Quality of Life and Functional Status  assessment  
and recording of hospital readmissions  in the master 
protocol study follow -up (Section 7) 
 Exclusion criteria updated to include breastfeeding  
 Added secondary ou tcomes  
 Section 1.1: Added backgro und information for additional 
treatments.  
 Appendix 1: Revised to refer to the Manual of Operations  
for the current state of arms and to the statistical analysis 
plan for the current analytic plan. Removed appendices 
1.1-1.3. 
 Appendices 3, 4 and 8: Retired  September 1 4, 2021  
 
  Page iii 
Version: 1.2, Date: 19OCT2021   
   
 Appendix 9: Added for arm E  
 Appendix 1 0: Added for arm F 
1.2  Appendix 1: Added definition of domain to clarify the 
difference between domain and arms   
 Appendix 9:  Added clinical use of crizanlizumab as an 
exclusion  October 19, 2021  
 
  
 
  Page iv 
Version: 1.2, Date: 19OCT2021   
   
 
Study Chair  
Clinical Coordinating 
Center  
 Judith Hochman, MD  
Harold Snyder Family Professor & Associate Director of 
Cardiology  
Senior Associate Dean for Clinical Sciences  
Co-Director, NYU -HHC Clinical and Translational Science Institute  
NYU Grossman School of Medicine  
530 First Avenue,  Skirball 9R  
New York, NY 10016  
Tel 212 -263-6927  
Email: judith.hochman@nyumc.org  
Principal investigator - 
lead for P2Y12 
inhibitor testing  
 Jeffrey S. Berger, MD  
Associate Professor of Medicine and Surgery  
Director, Center for the Prevention of Cardiovascular Disease  
NYU Grossman School of Medicine  
530 First Avenue,  Skirball 9R  
New York, NY 10016  
Tel: 212-263-4004  
Email: jeffrey.berger@nyulangone.org  
Principal investigator - 
lead for crizanlizumab 
testing  
 Scott D. Solomon, MD  
The Edward D. Frohlich Distinguished Chair  
Professor of Medicine  
Harvard Medical Sch ool 
Brigham and Women’s Hospital  
75 Francis St  
Boston, MA 02115  
Tel:  857-307-1960  
Fax: 857-307-1944  
Email: ssolomon@bwh.harvard.edu  
Principal investigator - 
lead for SGLT2i  testing  Mikhail N. Kosiborod, MD  
Vice President for Research  
Saint Luke’s Health System  
Professor of Medicine  
University of Missouri -Kansas City School of Medicine  
Tel:  816-931-1883  
Email: mkosiborod@saint -lukes.org  
Coordinating Center , 
Statistics, Data and 
Clinical  
 Stephen Wisniewski, PhD  
Professor of Epidemiology  
Vice Provost for Budget and Analytics  
University of Pittsburgh  
Email: STEVEWIS@pitt.edu  
 
Matthew Neal, MD  
Roberta G. Simmons Assistant Professor of Surgery   
Attending Surgeon, Division of Trauma and Acute Care Surgery  
Assistant Professor of  Clinical and Translational Science and 
Critical Care Medicine  
Departments of Surgery, Critical Care Medicine, and the Clinical 
and Translational Science Institute (CTSI), University of Pittsburgh  
 
  Page v 
Version: 1.2, Date: 19OCT2021   
   
 
  University of Pittsburgh Medical Center  
F1271.2 PUH 200 Lot hrop Street  
Pittsburgh, PA   15213  
Tel: 412 -647-1158  
Fax: 412 -647-1448  
Email: nealm2@upmc.edu  
Trial Biostatisticians  Scott Berry, PhD  
President, Senior Statistical Scientist  
Berry Consultants  
Tel 979 -575-6280  
Email: scott@berryconsultants.com  
 
Vidya Venugopal, PhD  
Epidemiology Data Center  
University of Pittsburgh  
Email: viv23@pitt.edu  
 
Eric Leifer, PhD  
NHLBI  
Email: leifere@nhlbi.nih.gov  
NHLBI Representative  Andrei Kindzelski, MD  
Email: kindzleskial@nhlbi.nih.gov  
IND Waiver  
ClinicalTrials.gov 
Identifier  [STUDY_ID_REMOVED]  
WIRB study number  20202415  
 
  Page vi 
Version: 1.2, Date: 19OCT2021   
   
Statement of Compliance  
 
In the United States this study will be conducted in accordance with the Code of Federal 
Regulations on the Protection of Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, 
and 812 as applicable, any other applicable US government research regulati ons, and 
institutional research policies and procedures. The International Conference on Harmonisation 
(“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to as “ICH -GCP” or 
“E6”) and the General Data Protection Regulations (GDPR) will  be applied only to the extent 
that it is compatible with FDA and DHHS regulations.  
 
Outside of the United States this study will be conducted according to local legal and regulatory 
requirements and regulations, ICH guidelines, and GDPR guidelines as app licable.  
 
The Principal Investigator will assure that no deviation from, or changes to, the protocol will take 
place without prior agreement from the sponsor and documented approval from the Institutional 
Review Board (IRB), except where necessary to elimi nate an immediate hazard(s) to the trial 
participants. All personnel involved in the conduct of this study have completed Human Subjects 
Protection Training.  
 
The signature below provides the necessary assurance that this study will be conducted  
according to all stipulations of the protocol including statements regarding confidentiality, and 
according to local legal and regulatory requirements, US federal regulations (if applicable), and 
ICH E6(R2) GCP guidelines.  
 
Version Date: Oct 19 . 2021  
 
 
 
 
Signature  of Principal  Investigator  Date  
 
 
 
 
 
Printed  Name  of Principal  Investigator  
 
 
 
 
 
Name  of Facility  
 
 
 
 
 
Location  of Facility  (City,  Country)  
  
 
  Page vii 
Version: 1.2, Date: 19OCT2021   
   
Table of Contents  
 
MASTER PROTOCOL SUMM ARY ................................ ................................ .......................  13 
1 INTRODUCTION, BACKGR OUND INFORMATION AND  SCIENTIFIC RATIONAL E ..... 15 
1.1 BACKGROUND INFORMA TION , SIGNIFICA NCE AND RELEVA NT LITERATURE  .....................  15 
1.1.1  Adaptive Design  ................................ ................................ ................................ . 17 
1.2 POTENTIAL RISKS & BENEFITS  ................................ ................................ ..................  17 
2 STUDY DESIGN  ................................ ................................ ................................ ............  17 
2.1 OVERALL STUDY DESIGN  ................................ ................................ ..........................  17 
2.2 RANDOMIZATION  ................................ ................................ ................................ ...... 17 
3 OBJECTIVES AND PURPO SE................................ ................................ ......................  18 
4 STUDY DESIGN AND END POINTS  ................................ ................................ ..............  18 
4.1 DESCRIPTION OF STUDY DESIGN  ................................ ................................ ...............  18 
4.2 STUDY ENDPOINTS ................................ ................................ ................................ ... 18 
4.2.1  Primary Study Endpoint  ................................ ................................ ......................  18 
4.2.2  Secondary Endpoints ................................ ................................ ..........................  19 
4.2.3  Additional Study Endpoints  ................................ ................................ .................  19 
4.2.4  Safety Endpoints  ................................ ................................ ................................  19 
5 STUDY ENROLLMENT  ................................ ................................ ................................ . 20 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................  20 
5.2 EXCLUSION CRITERIA  ................................ ................................ ...............................  20 
5.3 VULNERABLE SUBJECTS  ................................ ................................ ...........................  20 
5.4 STRA TEGIES FOR RECRUITMENT AND RETENTION  ................................ .......................  20 
5.5 DURA TION OF STUDY PARTICIPA TION  ................................ ................................ .........  21 
5.6 TOTAL NUMBER OF PARTICIPA NTS  ................................ ................................ .............  21 
5.7 PARTICIPA NT WITHDRA WAL OR TERMINA TION  ................................ .............................  21 
5.7.1  Reasons for Withdrawal or Termination  ................................ ...............................  21 
5.8 PREMA TURE TERMINATION OR SUSPENSION OF STUDY  ................................ ...............  21 
6 STUDY AGENT AND PROC EDURAL INTERVENTION  ................................ .................  21 
6.1 STUDY AGENTS  ................................ ................................ ................................ ....... 21 
6.2 DURA TION OF THERA PY  ................................ ................................ ............................  22 
7 STUDY PROCEDURES AND  SCHEDULE  ................................ ................................ .... 22 
7.1 STUDY SCHEDULE ................................ ................................ ................................ .... 22 
7.1.1  Visit 1 and Hospitalization Visits (see arm -specific appendices for deta ils) ...........  23 
7.1.2  28 days and/or Date of Hospital Discharge  ................................ ..........................  23 
7.1.3  90 days post-randomization  ................................ ................................ ................  23 
7.1.4  Potential one year post -randomization follow up  ................................ ..................  24 
7.2 CONCOMITA NT MEDICATIONS , TREA TMENTS , AND PROCEDURES  ................................ .. 24 
7.3 EXPEDITED CRITICA L AND MAJOR EV ENT REPORTING  ................................ .................  24 
7.4 DATA AND SAFETY MONITORING PLA N A ND STUDY HALTING RULES ..............................  24 
8 STATISTICAL CONSIDER ATIONS  ................................ ................................ ...............  24 
8.1 STATISTICAL A ND ANALYTICAL PLA NS (SAP)  ................................ ..............................  24 
 
  Page viii 
Version: 1.2, Date: 19OCT2021   
   
8.2 STATISTICAL MODELING FOR THE PRIMA RY ANALYSIS  ................................ .................  24 
8.3 MODEL PRIORS ................................ ................................ ................................ ........  25 
8.4 ASSESSING EFFECTIV ENESS  ................................ ................................ .....................  27 
8.5 ANALYSIS DATASETS  ................................ ................................ ................................  27 
8.5.1  Safety Analyses ................................ ................................ ................................ .. 27 
8.5.2  Adherence and Retention Analyses  ................................ ................................ .... 28 
8.5.3  Baseline Descriptive Statistics ................................ ................................ .............  28 
8.5.4  Planned Interim Analysis ................................ ................................ .....................  28 
8.5.5  Safety Review  ................................ ................................ ................................ .... 28 
8.5.6  Tabulation of Individual Response Data  ................................ ..............................  28 
8.5.7  Exploratory Analyses  ................................ ................................ ..........................  28 
8.6 SAMPLE SIZE ................................ ................................ ................................ ...........  28 
9 MEASURES TO MINIMIZE  BIAS  ................................ ................................ ...................  29 
9.1 ENROLLMENT /RA NDOMIZA TION  ................................ ................................ .................  29 
9.1.1  Enrollment  ................................ ................................ ................................ ..........  29 
9.1.2  Randomization  ................................ ................................ ................................ ... 29 
10 SOURCE DOCUMENTS AND  ACCESS TO SOURCE DA TA/DOCUMENTS  .................  29 
11 QUALITY ASSURANCE AN D QUALITY CONTROL  ................................ .....................  29 
12 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ................................ ...........................  29 
12.1  ETHICAL STA NDA RD  ................................ ................................ ................................ . 29 
12.2  INSTITUTIONAL REV IEW BOA RD  ................................ ................................ .................  29 
12.3  INFORMED CONSENT PROCESS  ................................ ................................ .................  30 
12.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ..... 30 
12.3.2  Consent P rocedures and Documentation  ................................ ............................  30 
12.4  POSTING OF CLINICA L TRIAL CONSENT FORM ................................ .............................  30 
12.5  PARTICIPA NT A ND DATA CONFIDENTIALITY  ................................ ................................ . 30 
13 DATA HANDLING AND RE CORD KEEPING  ................................ ................................  30 
13.1  DATA COLLECTION AND MA NAGEMENT RESPONSIBILITIES  ................................ ............  30 
13.2  STUDY RECORDS RETENTION  ................................ ................................ ...................  30 
13.3  PROTOCOL DEV IATIONS ................................ ................................ ............................  31 
13.4  PUBLICA TION AND DATA SHA RING POLICY  ................................ ................................ .. 31 
14 STUDY FINANCES  ................................ ................................ ................................ ....... 31 
14.1  FUNDING SOURCE ................................ ................................ ................................ .... 31 
14.2  COSTS TO THE PA RTICIPA NT  ................................ ................................ .....................  31 
15 CONFLICT OF INTEREST  POLICY  ................................ ................................ ...............  31 
16 REFERENCES  ................................ ................................ ................................ ..............  31 
APPENDIX 1: MASTER PROTOCOL STAT E OF ARMS ................................ .......................  36 
APPENDIX 2: DEFINITI ON AND DETERMINATION  OF OUTCOMES ................................ ... 37 
A2.1  APPROA CH TO ASCERTA IN MENT A ND V ERIFICA T ION OF OUTCOMES  ................................ .... 37 
A2.2  OUTCOME DEFINITIONS  ................................ ................................ ................................ . 37 
APPENDIX 4: PROPHYLA CTIC D OSE ANTICOAGULATION (ARM B) - RETIRED ..............  42 
 
  Page ix 
Version: 1.2, Date: 19OCT2021   
   
APPENDIX 5: ACTIV -4 BLOOD SAMPLING – PRO POSED SAMPLES AND TI MES FOR 
SITES PARTICIPATING IN MECHANISTIC STUDI ES AND BIOREPOSI TORY  ....................  43 
A5.1  INPA TIENT SA MPLING  ................................ ................................ ................................ .... 43 
A5.2  SAMPLE PROCESSING  ................................ ................................ ................................ ... 43 
A5.3  BIOREPOSITORY /CENTRAL LAB ................................ ................................ ......................  44 
APPENDIX 6: ADDITION AL DATA INCLUSIO N FROM OTHER TRIALS MERGED UNDER 
ACTIV -4 PLATFORM ................................ ................................ ................................ ............  45 
APPENDIX 7: BACKGROU ND AND RATIONALE FOR  ARM C: P2Y12 INHIBI TOR FOR ICU 
LEVEL OF CARE (SEVER E) COHORT ................................ ................................ .................  46 
A7.1   BACKGROUND A ND RATIONALE FOR ARM C ................................ ................................ .... 46 
A7.2.  ELIGIBILITY CRITERIA  FOR ARM C................................ ................................ ..................  46 
A7.2.1 Inclusion Criteria for Arm C  ................................ ................................ .................  46 
A7.2.2 Exclusion Criteria for Arm C  ................................ ................................ ................  46 
A7.3  STUDY AGENTS  ................................ ................................ ................................ ............  46 
A7.3.1.  ................................ ................................ ................................ ..........................  47 
Standard of Care Treatment  ................................ ................................ ...........................  47 
A7.3.2. P2Y12 Inhibitor  ................................ ................................ ................................ .. 47 
A7.3.3. Participants previously taking aspirin before randomization  ................................ . 47 
A7.4  DURATION OF TREA TMENT ................................ ................................ .............................  47 
A7.5  DISCONTINUA TION OF ST UDY INTERV ENTION  ................................ ................................ ... 48 
A7.6  STUDY SCHEDULE  ................................ ................................ ................................ ........  48 
A7.7  POTENTIA L RISKS & BENEFITS  ................................ ................................ .......................  49 
A7.7.1 Known Potential Risks ................................ ................................ .........................  49 
A7.7.2 Known Potential Benefits ................................ ................................ .....................  49 
A7.8  EVENT ADJUDICA TION ................................ ................................ ................................ ... 50 
A7.9  SAFETY ANALYSES  ................................ ................................ ................................ ....... 50 
A7.10  STATISTICAL ANALYSES  ................................ ................................ ..............................  50 
A7.11  REFERENCES  ................................ ................................ ................................ .............  50 
APPENDIX 8: ANTICOAG ULATION, PLUS P2Y12 INHIBITOR (ARM D) FO R NON -ICU 
LEVEL OF CARE (MODER ATE) COHORT – RETIRE D ................................ ........................  52 
APPENDIX  9: STANDARD OF CARE  PLUS CRIZANLIZUMAB (ARM E)  .............................  52 
A9.1   BACKGROUND A ND RATIONALE FOR ARM E ................................ ................................ .... 52 
A9.2  ELIGIBILITY CRITERIA FOR ARM E................................ ................................ ...................  53 
A9.2.1 Inclusion Criteria for Arm E ................................ ................................ ..................  53 
A9.2.2 Exclusion Criteria for Arm E ................................ ................................ .................  53 
A9.3  STUDY AGENT ................................ ................................ ................................ ..............  54 
A9.3.3 Participants receiving additional monoclonal antibody treatment(s)  ......................  55 
A9.3.4 Participants who become pregnant within 90 days of study treatment ...................  55 
A9.4  DURATION OF TREA TMENT ................................ ................................ .............................  56 
A9.5  DISCONTINUA TION OF ST UDY INTERV ENTION  ................................ ................................ ... 56 
A9.6  STUDY SCHEDULE  ................................ ................................ ................................ ........  56 
A9.7  POTENTIA L RISKS & BENEFITS  ................................ ................................ .......................  57 
A9.7.1 Known and Potential Risks  ................................ ................................ ..................  57 
A9.7.2 Known Potential Benefits ................................ ................................ .....................  58 
A9.8   EVENT ADJUDICA TION  ................................ ................................ ................................ .. 58 
A9.9   SAFETY ANALYSES  ................................ ................................ ................................ ...... 59 
 
  Page x 
Version: 1.2, Date: 19OCT2021   
   
A9.10  STATISTICAL ANALYSES  ................................ ................................ ..............................  59 
A9.11  SAFETY REPORTING  ................................ ................................ ................................ ... 59 
A9.12  REFERENCES  ................................ ................................ ................................ .............  59 
APPENDIX 10: STANDAR D OF CARE PLUS SGLT2  INHIBITOR  ................................ ........  61 
A10.1   BACKGROUND AND RA TIONALE FOR ARM F ................................ ................................ .. 61 
A10.2.  ELIGIBILITY CRITERIA FOR ARM F ................................ ................................ ................  62 
A10.2.1 Inclusion Criteria for Arm F  ................................ ................................ ................  62 
A10.2.2 Exclusion Criteria for Arm F  ................................ ................................ ...............  63 
A10.3  STUDY AGENTS  ................................ ................................ ................................ ..........  63 
A10.3.2. SGLT2 inhibitors  ................................ ................................ ..............................  63 
A10.3.3 Participants receiving additional Covid -19 therapies ................................ ...........  64 
A10.4  PARTICIPA NTS WHO BECO ME PREGNA NT WITHIN 90 DAYS OF STUDY TREA T MENT  ..............  64 
A10.5  DURA TION OF TREA TMENT  ................................ ................................ ...........................  64 
A10.6  DISCONTINUA TION OF ST UDY INTERV ENTION  ................................ ................................ . 64 
A10.7  STUDY SCHEDULE  ................................ ................................ ................................ ...... 65 
A10.8  POTENTIAL RISKS & BENEFITS  ................................ ................................ .....................  66 
A10.8.1 Known and Potential Risks  ................................ ................................ ................  66 
A10.8.2 Known Potential Benefits ................................ ................................ ...................  67 
A10.9E VENT ADJUDICA TION ................................ ................................ ................................ .. 68 
A10.10  SAFETY ANALYSES  ................................ ................................ ................................ ... 68 
A10.11  STATISTICAL ANALYSES  ................................ ................................ ............................  68 
A10.12  SAFETY REPORTING  ................................ ................................ ................................ . 68 
A10.13  REFERENCES  ................................ ................................ ................................ ...........  68 
 
 
  Page xi 
Version: 1.2, Date: 19OCT2021   
   
List of Abbreviations  
 
AE Adverse Event/Adverse Experience  
ARDS  Acute Respiratory Distress Syndrome  
ASA Acetylsalicylic Acid/Aspirin  
AT Arterial Thrombosis  
BMI Body mass index  
CFR Code of Federal Regulations  
CNS Central Nervous System  
CrCl Creatinine Clearance  
COVID -19 Coronavirus Disease  
CRF Case Report Form  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DIC Disseminated Intravascular Coagulation  
DKA Diabetic Ketoacidosis  
DSMB  Data and Safety Monitoring Board  
DVT Deep Ve in Thrombosis  
ECMO  Extracorporeal Membrane Oxygenation  
EDC Electronic Data Capture  
eGFR  Estimated Glomerular Filtration Rate  
FDA Food and Drug Administration  
FFR Federal Financial Report  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
GI Gastrointestinal  
HFNO  High-flow Nasal Oxygen  
HIPAA  Health Insurance Portability and Accountability Act  
HIT Heparin Induced Thrombocytopenia  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICU Intensive Care Unit  
IRB Institutional Review Board  
 
  Page xii 
Version: 1.2, Date: 19OCT2021   
   
ISM Independent Safety Monitor  
ISTH  International Society on Thrombosis and Haemostasis  
ITT Intent to Treat  
IV Invasive Ventilation  
JAK Janus kinase inhibitors  
KDIGO  Kidney Disease Improving Global Outcomes  
LAR Legally Authorized Representative  
MI Myocardial Infarction  
MOP  Manual of Procedures /Operations  
N Number (typically refers to  participants)  
NIH National Institutes of Health  
NIV Non-invasive ventilation  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Participants Research  
OSFD  Organ Support Free Days  
PE Pulmonary Embolism  
PI Principal Investigator  
POCUS  Point of Care Ultra Sound  
PTT Partial Thromboplastin Time  
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event/Serious Adverse Experience  
SCD Sickle cell disease  
SGLT2i  Sodium -glucose transport protein 2  inhibitor  
 
SOC  Standard of Care  
SOP Standard Operating Procedure  
US United States  
VTE Venous thromboembolism  
VWF  Von Willebrand Factor  
WHO  World Health Organization  
 
 
  Page 13 
Version: 1.2, Date: 19OCT2021   
   
Master Protocol Summary  
Title A Multicenter, Adaptive, Randomized, Open Label Controlled Platform 
Trial of the Safety and Efficacy of Antithrombotic  and Additional  
Strategies in Hospitalized Adults with COVID -19 
Short Title  ACTIV -4 ACUTE  
Brief Summary  This is a randomized , open label , adaptive  platform  trial to compare the 
effectiveness of antithrombotic  and additional  treatment strategies for 
prevention of adverse outcomes in COVID -19 positive inpatients  
 
Objectives  1. To determine the most effective antithrombotic  and additional 
treatment strateg ies for increasing the number of days free of organ 
support and reducing death . 
 
2. To determine the most effective antithrombotic and additional 
treatment strateg ies on the composite endpoint of death, pulmonary 
embolism (PE) , myocardial infarction (MI), ischemic stroke , or other 
systemic arterial thrombosis (AT) . 
 
3. To assess the safety of antithrombotic  and additional treatment  
strategies . 
 
4. To compare the effect  of antithrombotic  and additional treatment  
strategies on the endpoint of all -cause mortality in the study population.  
 
Assessment of efficacy and safety will yield information of the 
risk/benefit of different treatment  strategies in the study population . It 
will also yield information on outcomes specific to under -represented 
minority populations, specifically African - and Hispanic -descent 
persons.  
Methodology  Adaptive Randomized  Platform  Trial 
 
  Page 14 
Version: 1.2, Date: 19OCT2021   
   
Endpoint s Primary Endpoint:  21 Day Organ Support Free Days , which is defined 
as the number of days that a patient is alive and free of organ support 
through the first 2 1 days after trial entry. Organ Support is defined as 
receipt of invasive or non-invasive mechanical ventilation , high flow 
nasal oxygen , vasopress or therapy , or ECMO  support , with death  at 
any time  (including beyond 21 days) during the index hospitalization  
assigned -1 days.   
 
Secondary Endpoint s:  
 Categorization of the primary  endpoint into a three -level ordinal 
outcome ( Death, invasive mechanical ventilation without death, 
neither invasive mechanical ventilation nor death)  
 Categorization of the primary endpoint into a three -level ordinal 
outcome (Death, organ support (any respiratory or 
cardiovascular) without death, neither or gan support nor death) 
(for moderate illness severity at enrollment)  
 Days free of death and respiratory and cardiovascular  organ 
support and renal replacement therapy ( RRT) during I ndex 
Hospitalization through Day 28 .  
 Composite endpoint of death,  pulmonar y embolism, systemic 
arterial thromboembolism, myocardial infarction,  or ischemic 
stroke at hospital discharge or 28 days, whichever occurs first . 
 
Other Secondary Endpoints: Acute kidney injury . Individual endpoints 
comprising the  primary and  secondary endpoint  components;  death 
during hospitalization, WHO clinical scale  and 90 day mortality  
 
Safety Endpoint s:  Intervention specific  
 
Study Duration  Approxima tely 2 years  
Participant Duration  Hospital duration  with periodic contact post-discharge, including at 90 
days , and potentially at approximately 1 year  and thereafter  
Duration of assigned 
treatment strategy  During hospitalization (unless otherwise specified in description of arm)  
Population  Adult patients hospitalized for COVID -19  
Study Sites  Approximately 400 sites 
Number of 
participants  The sample size is described in each arm -specific appendix.  
Description of Study 
Agents  This platform trial allows for multiple therapies to be investigated in this 
trial over time. The trial is governed by a Master Protocol that describes 
the trial design, endpoint collection, primary endpoint, and 
inclusion/exclusion criteria. Different the rapies, referred to as arms, are 
detailed in arm -specific appendices. These arm -specific appendices 
work in a modular fashion as arms are removed and added to the 
platform trial.  
 
Key Procedures  Observation during hospitalization,  contact at 90 days post -enrollment, 
and collection of standard of care laboratory results.  Ancillary 
biobanking will be completed in consenting patients at capable centers . 
 
  Page 15 
Version: 1.2, Date: 19OCT2021   
   
Statistical Analysis  Inferences in this trial are based on a Bayesian statistical model, which 
considers the variation in outcomes by site, disease state , time,  and 
arm of the trial.  The specific analyses for each arm, including interim 
analysis schedule , are specified in each  arm-specific appendix , and 
associated statistical analysis plan  
 
1 Introduction, Background  Information and Scientific Rationale  
1.1 Background Information, Significance and Relevant Literature  
The severe acute respiratory syndrome coronavirus 2, which causes the highly contagious 
coronavirus disease 2019 (COVID -19), has resulted in a global pandemic.  
 
The clinical spectrum of COVID -19 infection is broad, encompassing asymptomatic infection, mild 
upper respiratory tract illness, and severe viral pneumonia with respiratory failure and death. The 
risk of thrombotic complications is increased, even as compared to other viral respiratory illnesses, 
such as influenza (1-4). A pro -inflammatory cytokine response as well as induction of procoagulant 
factors associated with COVID -19 has been proposed to contribute to thrombosis as well as plaque 
ruptu re through local inflammation (5). Patients with COVID -19 are at increased risk for arterial and 
vein thromboembolism (6), with high rates observed despite thromboprophylaxis (7). Autopsy 
reports have noted micro and macro vascular thrombosis across  multiple organ beds consistent 
with an early hypercoagulable state  (8). 
 
Notably, in COVID -19, data in the U .K. and U .S. document that infection and outcomes of infection 
are worse in African and Hispanic descent persons than in other groups. The reasons for this are 
uncertain.  
 
Viral Infection and Thrombosis  
A large body of literature lin ks inflammation and coagulation; altered hemostasis is a known 
complication of respiratory viral infections (9-11). Procoagulant markers are severely elevated in 
viral infections. Specifically, proinflammatory cytokines in  viral infections upregulate expression of 
tissue factor, markers of thrombin generation, platelet activation, and down -regulate natural 
anticoagulant proteins C and S  (11). 
 
Studies have demonstrated significant risk of deep venous thrombosis (DVT), pulmonary embolism 
(PE), and myocardial infarction (MI) associated with viral respiratory infections (10,12) . In a series 
of patients with fatal influenza H1 N1, 75% had pulmonary thrombi on autopsy (a rate considerably 
higher than reported on autopsy studies among the general intensive care unit population (13). 
Incidence ratio for acute myocardial infarction in the context of Influenza A is over 10  (14). Severe 
acute respiratory syndrome coronavirus -1 (SARS CoV -1) and influenza have been associated with 
disseminated intravascular  coagulation (DIC), endothelial damage, DVT, PE, and large artery 
ischemic stroke (11,15) . Obi et al. found that patient s with Influenza H1N1 and acute respiratory 
distress syndrome (ARDS) had a 23.3 -fold higher risk for pulmonary embolism, and a 17.9 -fold 
increased risk for deep vein thrombosis (16). Compared to those treated with systemic 
anticoagulation, those without treatment were 33 times more likely to suffer a VTE (16). 
 
Thrombosis, both microvascular and macrovascular , is a prominent feature in multiple organs at 
autopsy in fatal cases of COVID -19 (8). Thrombosis may thus contribute to respiratory failure, renal 
failure , and hepatic injury in COVID -19. The number of megakaryocytes in tissues is higher than in 
other forms of ARDS, and thrombi are platelet -rich based on specific staining.  Thrombotic s troke 
 
  Page 16 
Version: 1.2, Date: 19OCT2021   
   
has been reported in young COVID -19 patients with no cardiovascular ris k factors (17). Both arterial 
and venous thrombotic events have been seen in increasing numbe rs of hospitalized patients 
infected with COVID -19. The incidence of thrombosis has ranged from 10 to 30% in hospitalized 
patients; however, this varies by type of thrombosis captured (arterial or ve in) and severity of illness 
(ICU level care, requiring me chanical ventilation, etc.).  
 
D-dimer, a biomarker of fibrin formation and degradation, is elevated in conditions associated with 
thrombosis, and has been strongly  associated with increased mortality among patients with COVID -
19 (1, 2, 3, 6, 7). In a retro spective analysis of 191 patients with COVID -19, Zhou et al. found that 
non-survivors were more likely to have D -dimer levels > 1 ug/mL than survivors (81% v 24%) ( 5). 
Similarly, in a study of 183 patients, Tang et al. noted that non -survivors had signific antly higher D -
dimer values on admission than survivors (2.12 v 0.61 ug/mL, P  < 0.001) ( 6). In a retrospective 
study, patients with COVID -19 and D -dimer values >  6-fold upper limit of normal had lower 28 -day 
mortality when treated with prophylactic  anticoa gulation  compared with no anticoagulation (32.8% v 
52.4%, p=0.017) (8). Data suggest a strong association between D -dimer and the outcomes of ICU 
intubation and all -cause mortality, and the association between D -dimer and (1) mortality, (2) critical 
illness, (3) acute kidney injury, and (4) thrombo tic risk is increased at a D-dimer between 1X to 2X 
the upper limit of normal. Thrombosis is also increased in those with elevated inflammation indexed 
by C-reactive protein level ( 20). Preliminary data sugg est that platelet activity is increased in 
COVID -19(18) and that biomarkers of platelet activity correlate with the incidence of death or 
thrombosis in hospitalized patients with COVID -19. Platelet -fibrin thrombi have been observed in 
alveolar capillaries, where they may affect gas exchange  (8), and in the renal peri -tubular 
capillaries, where they may contribute to acute tubular necrosis and renal dysfunction . Consistently, 
autopsy findings demonstrate an increase in the number of circulating megaka ryocytes outside the 
bone marrow and lung. Finally, thrombotic events have been noted – even among patients treated 
with full dose anticoagulation.  
 
There may be racial and ethnic differences in response to COVID 19 infection. It is hypothesized 
that antit hrombotic interventions being tested will benefit all patients, including those who are 
disproportionately affected.  (21–25, 26).  
The ACTIV -4 ACUTE investigators postulate that strategies designed to reduce the need for organ 
support, including  antithromb otic, anti -inflammatory and other therapies that offer other 
mechanisms for organ protection,  will improve clinical outcomes in COVID -19 patients . This 
protocol intends  to define the optimal regime n in an adaptive randomized trial  of patients 
hospitalized with COVID -19 at risk for adverse clinical outcomes. The primary outcome will be the 
number of days free of organ support within 2 1 days after randomization. This primary outcome was 
selected because it is pragmatic and yet objecti ve and clinically relevant . Organ support free days is 
defined by days in which patient is not on invasive or non -invasive mechanical ventilation, high flow 
nasal oxygen, vasopressor therapy , or ECMO support  (see Appendix 2), with death assigned  the 
value of –1 days.  
 
Additional treatment strategies  
Data from the multiplatform randomized controlled trial (mpRCT) demonstrated that (1) therapeutic 
dose anticoagulation with heparin was not beneficial in improving clinical outcomes compared to 
standard of care prophylactic dose heparin in severe ly ill (ICU level of care ) patients, and (2) 
therapeutic dose anticoagulation with heparin was beneficial in improving organ support f ree days 
compared to standard of care prophylactic dose heparin in  moderate ly ill (hospitalized and no t 
requiring organ support)  patients.  (27, 28)  However, t here remains significant residual risk for 
adverse clinical outcomes and excess mortality for sev erely ill as well as  moderate ly ill patients. 
 
  Page 17 
Version: 1.2, Date: 19OCT2021   
   
Antithr ombotic regimens that are shown to be efficacious  will be combined in clinical practice with 
other agents to treat COVID -19 hospitalized patients.  This adaptive platform trial will test other 
promising agents when added to proven therapies , such as heparin . The rationale and risks for 
each agent will be included in the arm-specific appendix.  
1.1.1  Adaptive Design  
This platform trial will have multiple arms, which may be dropped or added as the platform trial 
progresses. Sample size will be flexible : the trial will be stopped for efficacy or futility based on pre -
determined statistical thresholds as de fined in the arm-specific appendi ces. Each arm will have an 
adaptive component  for determinations of futility or  success. 
1.2 Potential Risks & Benefits  
See arm-specific Appendi ces for details  
 
2 Study Design  
2.1 Overall Study Design  
This trial design is built as a process – with the possibility of multiple interventions being 
investigated  simultaneously or in series . The tri al is designed to be flexible, and these flexible 
aspects are planned as part of the protocol. This trial may incorporate a flexible number of 
interventions, and the number of interventions may evolve as the science evolves. Intervention 
arms will be added  or dropped based on criteria defined in arm -specific appendices . Co-enrollment 
in other trials is permitted as long as the other trial does not test agents with that present a safety 
concern or  scientific contraindication.  Arm-specific appendices will add ress concerns about co -
enrollment.  
 
  
2.2 Randomization  
Randomization assignments are at the participant level and are assigned  at baseline. 
Randomization will be  stratified by  enrolling site and may also be stratified by severity of illness 
and/or other arm-specific criteria. In general, allocation will be equally distributed across arms for 
which the participant is eligible , but may be altered with future arm -specific appendices.  If a 
participant is eligible for multiple arms, they would be equally rando mized (1:1) to all eligible arms.   
 
  Page 18 
Version: 1.2, Date: 19OCT2021   
   
 
3 Objectives and Purpose  
The overarching objective of this adaptive platform design is to iteratively learn which treatment  
strateg ies, including but not limited to antithrombotic strategies,  are best for reducing  the primary, 
secondary, and safety outcomes. Additional alternative strategy( -ies) will be compared to the 
current standard of care arm, which may trigger  new standard of care designated arms as 
appropriate based on interim analysis results  and evolving l iterature . This process will continue until 
no new strategies replace the standard of care  or potential options for additional interventions are 
exhausted . 
4 Study Design and Endpoints  
4.1 Description of Study Design  
This trial design is built as a process – with the possibility of multiple interventions being 
investigated. It is an open label randomized trial of patients hospitalized for COVID -19 who are 
assigned to different treatment  regimens.  
4.2 Study Endpoints  
4.2.1  Primary Study Endpoint  
21 Day Organ -Support free -days. The primary endpoint is the number of days that a patient is alive 
and free of organ support through 2 1 days after trial entry. Organ support is defined by receipt of 
invasive or non-invasive mechanical ventilation, high flow nasal oxygen , vasopresso r therapy , or 
ECMO  support . If the patient die s at any  time durin g the index hospital stay  through 90 days , they 
are assigned the worst possible score of –1. 

 
  Page 19 
Version: 1.2, Date: 19OCT2021   
   
4.2.2  Secondary Endpoint s 
 Categorization of the primary endpoint into a three -level ordinal outcome (Dea th, invasive 
mechanical ventilation without death, neither invasive mechanical ventilation nor death)  
 Categorization of the primary endpoint into a three -level ordinal outcome (Death, organ 
support (any respiratory or cardiovascular) without death, neithe r organ support nor death) 
(for moderate illness severity at enrollment)  
 Days free of death and respiratory and cardiovascular  organ support and renal replacement 
therapy (RRT) during I ndex Hospitalization through Day 28 .  If the patient dies at any time 
during the index hospital stay  through 90 days , they are assigned the worst possible score 
of –1. 
 A composite endpoint of death, pulmonary embolism, systemic arterial thromboembolism, 
myocardial infarction, or ischemic stroke during hospitalization or at 28 days after enrollment 
(whichever is earlier)  – “major thrombotic events or death”  
 28 Day Hospital free days (non -ICU level patients)  
 28 Day Ventilator -Free Days  (ICU level patients)  
 28 Day Vasopressor -Free Days  (ICU level patients)  
 28 Day Renal Replaceme nt Free Days  
 Hospital readmission within 2 8 days  
 Acute kidney injury    
 Deep vein thrombosis  
 Pulmonary embolism  
 Systemic arterial thrombosis or embolism  
 Myocardial infarction  
 Ischemic stroke  
 Renal replacement therapy   
 Use of extracorporeal membrane oxygenation (ECMO)  support  
 Mechanical circuit (dialysis or ECMO) thrombosis  
 WHO ordinal scale (peak scale over 28 days, scale at 14 days, and proportion with 
improvement by at least 2 categories compared to enrollment, at 28 days)  
 All-cause mortality  at 28 days  
 All-cause mortality during initial hospitalization (includes death after 28 days)  
 All-cause mortality at 90 days  
 
4.2.3  Additional Study Endpoints  
 Individual endpoints of the thrombotic events composite endpoint  
 Length of Hospital stay  
 Exploratory endpoin ts  
o Cardiac injury (e.g. , troponin)  
o Trajectories of biomarkers related to COVID -19 
o Hospital readmission within 90  days  
o All-cause mortality at 1 year  
 
See arm-specific Appendi ces for additional tertiary endpoints of interest specific to arm. 
4.2.4  Safety Endpoints  
 Safety Endpoint s:  Intervention specific  
 
 
  Page 20 
Version: 1.2, Date: 19OCT2021   
   
5 Study Enrollment  
5.1 Inclusion Criteria  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
 ≥ 18 years of age  
 Hospitalized for COVID -19* 
 Enrolled w ithin 72 hours of hospital admittance or 72 hours of positive COVID test  
 Expected to  require hospitalization for > 72 hours  
 See arm-specific Appendi ces for additional criteria and details  
 *It is strongly recommended to confirm SAR SCoV2 with a positive PCR or  other commercial or public health 
assay  prior to randomization. At centers where th ere is a delay in confirming the diagnosis,  a sufficiently  high 
clinical suspicion is sufficient to proceed with randomization as long as confirmation is expected  within 24 
hours . 
 
5.2 Exclusion Criteria  
 Imminent death  
 Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization  
 Pregnancy  and breas tfeeding  
 See arm-specific appendi ces for additional criteria and details . 
5.3 Vulnerable Subjects  
Critically ill patients with COVID -19 may not have capacity to provide consent. Th is trial  will include 
participants who have no capacity to consent only if their legal proxy is able to consent on their 
behalf. It has become increasingly apparent that indi viduals with COVID -19 are at risk for adverse 
outcomes . Patients without the capacity to consent for themselves will have a potential for direct 
benefit by being part of the trial.  
 
Capacity assessment will be conducted by the treating physician or an inde pendent medical 
provider with appropriate expertise based on the standard clinical assessment of capacity and 
communicated to the study team. Surrogate consent will be provided by the subject’s Legally 
Authorized Representative as defined by local policies  and state/country regulations.  
 
Consent will be obtained from the LAR before any study related procedures begin. Participants’ 
capacity will be monitored throughout the study by working with the treatment team. Once the 
participant regains the capacity to  consent, they will be informed of their participation in the study 
and will have an opportunity to withdraw from further participation in the study. The enrollment of 
patients without capacity is important because critically  ill patients, especially those who are not 
ambulatory, are at higher risk of developing adverse outcomes . 
5.4 Strategies for Recruitment and Retention  
Listings of patients admitted to the participating sites with COVID -19 may be reviewed for eligibility 
by the  study team, to identify and recruit potential participants, until study enrollment goals have 
been met. The study team should communicat e with  the inpatient care team. All treating physicians 
will be informed of the study and will have the option to advis e of any conditions that would preclude 
any individual patient being approached.  
 
  Page 21 
Version: 1.2, Date: 19OCT2021   
   
5.5 Duration of Study Participation  
Duration of study participation is 90 days from enrollment , and potential follow -up at approximately 
one year  and thereafter.   
 
5.6 Total Num ber of  Participants  
The total sample size for the platform trial is not pre -determined.  The sample size for each arm will 
be set in the arm -specific appendix and will incorporate an adaptive design.  There will be interim 
monitoring to allow early stopping for futility, efficacy, or safety. If one strategy proves to be 
efficacious, then this strategy may become the reference arm for comparison(s) with new 
experimental treatment(s). New arms can be introduced according to scientific and public health 
needs. Some arms may not relate solely to antithrombotic therapy.  
5.7 Participant Withdrawal or Termination  
5.7.1  Reasons for Withdrawal or Termination  
Participants are free to withdraw from participation in the study at any time upon request.  
Discontinuation of a study agent, regardless of the reason, e.g. patient or physician request , or 
adverse event,  does not constitute study withdrawal. Patient data will still be collected as planned 
and analyzed as intent to treat  unless the participant withdraws consent for continued foll ow-up.  
An investigator may terminate participation in the study if  any situation occurs such that continued 
participation in the study would not be in the best interest of the participant  
5.8 Premature Termination or Suspension of Study  
All deaths and DSMB -specified severe adverse events within the study period will be reviewed by 
the DSMB. The decision to stop or suspend the study , or an arm of the study,  will be made by the 
DSMB after considering the totality of the data and the benefit -risk of contin uing the study.  
 
This study , or an arm of the study,  may be temporarily suspended or prematurely terminated if there 
is sufficient reasonable cause.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
 Determination of  unexpected, significant, or unacceptable risk to participants in a strategy, 
such as excess mortality and/or major bleeding (this will be determined by the oversight data 
safety monitoring plan ) 
 Demonstration of efficacy or lack thereof that would warrant  stopping   
 Insufficient compliance to protocol requirements  
 Data that are not sufficiently complete and/or evaluable  
 Determination of futility  
 
The s tudy may resume once concerns about safety, protocol compliance, data quality are 
addressed and satisfy the  sponsor, IRB and/or FDA.  
 
6 Study Agent and Procedural Intervention  
6.1 Study Agents  
Each arm in this platform trial will include different treatment strategies. Information about the 
treatment strategies for a given arm can be found in the arm-specific appendi ces. 
 
  Page 22 
Version: 1.2, Date: 19OCT2021   
   
6.2 Duration of Therapy  
Once participants are randomized to a treatment strategy ( arm), they will remain on treatment for 
the dura tion specified by the relevant appendix . However, if a participant randomized to one arm 
develops an indication for a differ ent strategy (e.g., thrombotic event, worsening clinical s tatus ), the 
participant will be treated based on institutional guidelines with any measures required by local 
clinical judgment.  
7 Study Procedures and Schedule  
7.1 Study Schedule  
 
Activity  Screening/  
Enrollment  Hospital 
Duration  28 days 
and/or 
hospital 
discharge***  
 90-days post 
randomization 
and longer 
term follow -up 
Eligibility      
Consent  X    
Demographic and Medical 
History  X    
Assessment of 
Inclusion/Exclusion criteria  X    
Self-reported race/ethnicity and 
gender  X    
Study Drug Administration      
Randomization  X    
Study treatment  X X   
Study Procedures      
Height  X    
Weight  X    
Vital signs  X    
Concomitant medications  X X   
WHO ordinal assessment  X X X X 
Quality of Life and  Functional 
Status# X   X 
Outcomes Assessment#  X X X 
SOC Laboratory Assessments      
Chemistry panel  X X X       
Hematology panel  X X   
D-dimer*  X    
Blood Group**  X    
 
See arm -specific appendi ces for additional measures  
 
*D-dimer is strongly recommended for measurement in all participants  as close to the time of randomization 
as feasible .  
**Blood group will come from hospital record or self-report if available. Biospecimens see appendix 4.   
 
  Page 23 
Version: 1.2, Date: 19OCT2021   
   
***Assessments indicated in the table above will be ascertained at discharge, or at 28 days, whichever comes 
first. Participants must be followed for vital status until discharged from the hospital or another care facility (if 
transferred on organ support) up to 90 days. To maximize retention, participants will be contacted 
intermittently post -discharge  and that contact will be recorded in the EDC .  
#Participants may be assessed for functional status and quality of life that reflects baseline status pre -COVID 
illness and functional and vital status and quality of life  at 90 days  and longer -term follow -up (Instruments 
detailed in the manual of operations) .  Participants may be contacted in the future , including  after this study is 
over to collect information about their health status ( e.g. qualit y of life, functional and vital status) and 
ascertain their interest in  other studies about COVID -19. 
 
 
Laboratory Procedures/Evaluations  
See arm-specific appendi ces. 
 
All analyses will be performed on SOC  labs and procedures done for usual care. The standard 
operating procedures for samples to be collected for research purp oses are included as Appendix 
5. All research samples will be timed with clinical lab draws to limit provider exposure.   Collection of 
research sa mples as outlined in Appendix 5  is strongly encouraged where safe and feasible.  
7.1.1  Visit 1 and Hospitalization Visits  (see arm -specific appendi ces for details ) 
Visit 1 (Screening and Randomization)  
1. Informed consent obtained  
2. Assessment of inclusion/exclusion criteria  assessed  
3. Screening,  consisting of reviewing participant medical history and information in their chart 
such as height, weight, vital signs, and normal clinically performed laboratory assessments, 
including pregnancy test for all women of childbearing age.  
4. If confirmed eligible, following randomization, initiation of treatment with the assigned 
strategy  
 
Hospitalization Visits  
1. Recording of specifics of study treatment and adherence according to assigned arm 
2. Laboratory assessments as part of standard of care  
3. Daily WHO ordinal asse ssment  
4. Ongoing daily outcomes and safety assessment  
7.1.2  28 days and/ or Date of H ospital D ischarge  
1. Record ing of  outcomes and safety assessments as reported by participant or observed by 
investigator  
2. WHO Ordinal Assessment  
3. Record ing of  vital status and ascertainment of events  
4. Record ing of  participant’s adherence to treatment strategy , if patient is in hospital  
 
 
These assessments will be ascertained at discharge, or at 28 days, whichever comes first. 
Participants must be followed for vital status until discharged from the hospital or another care 
facility (if transferred on organ support) up to 90 days.  
7.1.3  90 days  post -randomization  
1. Recording of vital status  
2. May include q uality of life and functional status  assessment  
 
  Page 24 
Version: 1.2, Date: 19OCT2021   
   
3. May includ e recording of hospital readmissions  
7.1.4  Potential o ne year  post -randomization  follow up  
1. Recording of vital status  
2. May include q uality of life and functional status  assessment  
3. May include recording of hospital readmissions  
 
Participants  may be contac ted by a research contact and/or by the participating hospital study team  
periodically for longer term follow -up to collect information about their health status (e.g. quality of 
life, functional  and vital  status) and ascertain their interest in other stud ies about COVID -19. To 
maximize retention, participants will be contacted intermittently (e.g. once or twice  post-discharge). 
Discharge visits must be completed.  
7.2 Concomitant Medications, Treatments, and Procedures  
Concomitant medications taken during study participation will be recorded on the case report forms 
(CRFs). Concomitant medications to be recorded are:  
 Antithrombotics  (e.g., aspirin , heparin , and other agents ) 
 Any treatments  used for the treatment of COVID -19 infection (e.g., remdesivir, systemic 
steroids, IL -6 inhibitor such as  tocilizumab , Janus kinase (JAK) inhibitors, convalescent 
plasma ) 
 Others speci fied in arm -specific appendi ces 
7.3 Expedited Critical and Major Event Reporting  
All efficacy and safety outcome events will be assessed and documented in the participants’  study 
records.  The ACTIV -4 Platform will have a uniform policy for reporting adverse events to ensure 
that all events are assessed quickly and are submitted to the DSMB, IRB(s), and other groups as 
needed (e.g., FDA) , following each group’s reporting guidelines and timelines.   Events meeting the 
independent DSMB -specified criteria will be reported immediately and within the ti me frames 
specified by the DSMB.    
 
Sites are required to follow their local reporting guidelines.  
7.4 Data and Safety Monitoring Plan and Study Halting Rules  
The ACTIV -4 Platform will have a uniform Data and Safety Monitoring Plan, encompassing all 
research carried out within the Platform.  
 
8 Statistical Considerations  
8.1 Statistical and Analytical Plans (SAP)  
There will be a formal Statistical Analysis Plan (SAP) and each arm  added to the trial  will have its 
own arm -specific SAP. This will include the primary analysis, the primary comparison, futili ty and 
success rules, and interim analysis schedule. The SAP will be created prior to the first interim 
analysis for the study and each arm -specific SAP will be created before the first interim analysis for 
that arm.  
8.2 Statistical Modeling  for the Primary An alysis  
Inferences in this trial are based on a Bayesian statistical model for the ordinal primary outcome, 
organ -support free -days (OSFD) . There is a single Bayesian model for the primary outcome across 
 
  Page 25 
Version: 1.2, Date: 19OCT2021   
   
each arm and subpopulation. The Bayesian model is an ordinal cumulative logistic regression 
model described below.  
 
Let 𝑌𝑖={−1,0,1,…,21} denote the ordinal outcome (OSFD) for patient 
 . The probability of patient 
 observing 
  OSFD or less is denoted as 
 . The parameters in the model are 
structured so that a value > 0 implies treatment benefit, and hence an odds -ratio > 1 implies 
treatment benefit.  In this section we describe the generic model for the study, but arm-specific 
appendi ces may va ry in its modeling assumptions. The generic primary analysis model is 
formulated as follows:  
 
log(𝜋𝑖𝑦
1−𝜋𝑖𝑦)=𝛼𝑦,𝑠−[𝜈𝑆𝑖𝑡𝑒,𝑠+𝜆𝑇𝑖𝑚𝑒,𝑠+𝜃𝑎,𝑠+𝛽𝐴𝑔𝑒,𝑠+𝛽𝑆𝑒𝑥,𝑠] 
 
1. The “ subtype ” variable , s, corresponds to the two patient subgroups defined  by disease 
severity:  
a. subtype = 1 is non -ICU level care  
b. subtype  = 2 is ICU -level care  
2. The “site” variable is the clinical site within the trial .  These will be site effects estimated 
separately within the non -ICU and ICU level of case disease states . 
3. The “time” variable is an indicator of the month of enrollment in the trial, numbered 
decreasing from the first enrollment to the last enrollment for the analysis.   The time effects 
will be estimated separately within the non -ICU and ICU level of case disease state s. 
4. The “arm” the patient is randomized to is labeled as a.  The effects of arm are modeled by 
the disease state . 
5. The “age” variable is a categorical classification of age as ≤ 39, 40 -49, 50 -59, 60 -69, 70 -79, 
and 80+.  The age effects will be estimated  separately within the non -ICU and ICU level of 
case disease states . 
6. The “sex” variable is sex at birth.   The sex effects will be estimated separately within the 
non-ICU and ICU level of case disease states . 
If additional covariates  (e.g. race and ethnicity) are added to the model they will by default, unless 
otherwise specified, vary by disease state .   
If patients are randomized simultaneously to multiple arms the primary analysis will adjust using a 
covariate for each other random ized agent assigned.  In addition, some interactions between 
randomized arms may be included.  
The 
  parameters are the baseline rates of the ordinal outcome, which are modeled 
separately by disease subtype .  
8.3 Model Priors  
The treatment effects for arm a, within disease s ubtype  s are modeled with the 𝜃𝑠 parameters. The 
 parameters model any covariate effects included in the model.   The 
  parameters model the 
effect of time within the pandemic.  
 
  Page 26 
Version: 1.2, Date: 19OCT2021   
   
The ordinal endpoint rates are modeled using an inverse Dirichlet model where the individual 
probabilities for the 2 3 outcomes are  based on 1 patient ’s weight on equally likely outcomes.   
 
The site effects, 
 , are modeled using a hierarchical mo del where site is nested within the 
country of the site : 
 
 
A referent site, expected to be the largest enrolling site, will be set such that 
  The hyper -
parameters of the site hierarchical model are separate by disease state s. 
The effect of time ( T) is modeled using a second -order normal dynamic linear model  separately by 
disease state, s. The most recent two time periods are modeled as the referent time epochs with 
the time parameters set to 0. The preceding time epochs are modeled as a norm al dynamic linear 
model as:  
 
 
 
The treatment effect parameters are set against a control arm, which will be labeled in the arm -
specific appendix. The treatment effect for the control arm, labeled as arm a = 1, will be set to 0 for 
each of the disease states:  
𝜃1,𝑠≡0. 
The effect of each treatment  arm introduced will typically be modeled hierarchically across disease 
subtype s.  The modeling of the treatment arms will be specified in appendices.   
Any additional covariates included in the model will have independent  N(0,1) priors unless 
otherwise specified.  
 
  Page 27 
Version: 1.2, Date: 19OCT2021   
   
8.4 Assessing Effectiveness  
The treatment effect parameters, 𝜃, represent the log -odds ratio, of the treatment , for the 
cumulative logistic for the ordinal model. In this parametrization an odds ratio > 1, or a log -odds 
ratio > 0, signifies improved outcomes relative to the referent control treatment. The odds -ratio 
parameter exp(𝜃), labeled OR, will be u sed to summarize the treatment effect relative to control or 
exp(𝜃𝑎1−𝜃𝑎2) for the odds -ratio between arms a1 and a2. The posterior mean, median, standard 
deviation, and 95% credible intervals for the odds -ratio will be used to summarize relati ve treatment 
effects.  
The posterior probability that an arm, a1, is superior to another arm, say, a2, is: 
Pr(𝜃𝑎1>𝜃𝑎2). 
This probability will be used for triggers of superiority of one arm to another arm.  
The posterior probability that an arm, a1, is superior to another arm, say, a2, by a specified 
difference on the odds -ratio scale is:  
Pr(exp(𝜃𝑎1)>exp(𝜃𝑎2)+𝛿). 
This probability will typically be used for futility. If the probability is small that a treatment has benefit 
above a control o f some specified amount  (
), the arm may be dropped for futility.  
8.5 Analysis Datasets  
The intention -to-treat (ITT) analysis dataset will be the source of data for primary analyses. This will 
include all randomized participants regardless of actual receipt or compliance with therapy. The 
safety analysis set will consist of all participants who received at least one dose of study 
medication. The per protocol analysis will be conducted based on adherence to assigned treatment ; 
this dataset will support sensitivity analyses to complement the primary ITT analyses.  
 
The ITT group for an arm consists of the participants that were randomized in the platform that were 
eligible to be randomized to that arm.  This may vary fro m the platform  ITT population, which 
consists of all participants randomized.  
 
Participants who are randomized to receive one strategy may in fact be treated with another 
strategy based on health status and provider discretion. Exploratory analys es will estimate the 
causal effect of the treatment for these participants  using marginal structural modelling techniques. 
These techniques use inverse probability weighting methods that are based on patient -level 
covariates to create comparable groups for the analysis.  
8.5.1  Safety A nalyses  
Monitoring for safety will be  conduct ed continuous ly. For each arm -specific appendix potential 
adverse events of importance will be identified.  A Bayesian monitoring rule will be used to 
summarize the adverse event rates across all arms for the ad verse events of importance within 
each arm -specific  appendix.  A Bayesian prior distribution of a beta (0.1, 0.9) will be used to model 
the likelihood of each adverse event of importance. For each adverse event of importance , the 
 
  Page 28 
Version: 1.2, Date: 19OCT2021   
   
posterior mean event rates , the posterior mean of the difference between each arm, and the 95% 
credible intervals for the risk -difference and odds -ratio will be summarized.  
8.5.2  Adherence and Retention Analyses  
The primary analysis is by intention to treat. Per protocol analysis will be  conducted based on 
adherence to assigned treatment. For any scheduled follow -up post hospital discharge e very effort 
will be made to recontact participants  who are unreachable. Due to the short trial participation 
timeline, excellent patient retention  is anticipated . 
8.5.3  Baseline Descriptive Statistics  
All variables will be summarized using mean, median, standard deviation, and range (for continuous 
variables) and frequency (for categorical variables). Treatment groups will be compared with 
respect to base line characteristics to verify randomization balance.  
8.5.4  Planned Interim Analysis  
An independent data safety and monitoring board (DSMB) will review all interim analyses prepared 
by an unblinded statistical  analysis committee.  
8.5.5  Safety Review  
Monitoring for saf ety will be conducted continuously.  The DSMB will be monitoring safety for each 
arm-specific appendix.  The DSMB monitoring plan includes guidance on stopping specific arms  for 
safety concerns .    
8.5.6  Tabulation of Individual Response Data  
The composite outcom e evaluated will be tabulated and broken down by component (e.g., death, 
pulmonary embolus, myocardial infarction, etc.). Note that some participants may experience more 
than one component of the primary endpoint.  
8.5.7  Exploratory Analyses  
Exploratory analyses will be conducted in a subset of participants on whom additional clinical and 
basic science assays are performed. These will be descriptive and hypothesis -generating.  
8.6 Sample Size  
Sample size for the platform trial is not pre -determined. The platform trial will run as long as there is 
a need and there are investigational arms enrolling. The sample size for each arm will be specified 
in the arm -specific appendix. Interim analyses for each arm will take place in the platform trial and 
detailed in the arm -speci fic appendix. Conclusions of futility or superiority may be drawn specific to 
a patient subtype . Effort will be taken to conduct all interim analyses at the same time in the 
platform trial since there is a single Bayesian model of the efficacy of all arms conducted. If one 
strategy proves to be efficacious, then this strategy may become the reference arm for 
comparison(s) with new experimental treatment(s). New arms can be introduced according to 
scientific and public health needs.  
 
 
 
  Page 29 
Version: 1.2, Date: 19OCT2021   
   
9 Measures to Minimize B ias 
9.1 Enrollment/Randomization  
 
9.1.1  Enrollment  
 
1. Patients hospitalized for COVID -19 are screened daily within the eligibility time window for 
inclusion/exclusion criteria. Any patient who meets all inclusion criteria and no exclusion criteria 
will be approached f or enrollment.  
 
2. Patients remain in the intention -to-treat group if they receive  another treatment strategy after 
randomization.  
 
9.1.2  Randomization  
Randomization assignments are performed for participants  at baseline. Randomization will be equal 
across all arms a patient is eligible. Randomization stratification will be done by site, and disease 
subtype  (ICU and non-ICU level care)  and/or other arm -specific criteria.   
 
 
10 Source Documents and Access to Source Data/Docume nts 
The ACTIV -4 Platform will have uniform policies describing what source documents are, how to 
make corrections, and who can access them.  
 
11 Quality Assurance and Quality Control  
The ACTIV -4 Platform will have uniform policies for quality assurance at the data entry level and 
site monitoring.  
 
12 Ethics/Protection of Human Subjects  
12.1 Ethical Standard  
The investigator will ensure that this study is conducted in full conformity with Regulations for the 
Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR 
Part 56, and/or the ICH E6.  
 
12.2 Institutional Review Board  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form 
must be obtained before any participant is enrolled. Any amendment to the protocol will require 
review and approval by the IRB before the changes are implemented to the study. All changes to 
the consent form will be IRB approved; a determination will be made regarding whether previously 
consented participants need to be re -consented.  
 
  Page 30 
Version: 1.2, Date: 19OCT2021   
   
12.3 Informed Consent Process  
12.3.1  Consent/Assent and Other Informational Documents Provided  to Participants  
Consent forms describing in detail the study agent, study procedures, and risks are given to the 
participant , and written documentation of informed consent is required prior to starting 
intervention/administering study product.  
 
A written consent will be sought from every participant via a face to face consenting process or 
remotely by using an e-consent option as per IRB approved method.  
12.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the indiv idual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Informed consent will be 
obtained following institutional COVID policy to protect study staff.  
 
An extensive discussion of risks and possible benefi ts of participation will be provided to the 
participants and their families. Consent forms will be IRB -approved and the participant will be asked 
to read and review the document. The investigator  or designee  will explain the research study to the 
participa nt and answer any questions that may arise. Participants will have the opportunity to 
carefully review the written consent form and ask questions prior to signing. The participants should 
have the opportunity to discuss the study with their surrogates or t hink about it prior to agreeing to 
participate. The participant will sign the consent document prior to any procedures being done 
specifically for the study. The participants may withdraw consent at any time throughout the course 
of the trial. A copy of th e signed informed consent document will be provided to participants. The 
rights and welfare of the participants will be protected by emphasizing to them that the quality of 
their medical care will not be adversely affected if they decline to participate in  this study.  
 
Participants who have no capacity to consent for themselves will have a surrogate consenting 
process via legally authorized representative.  
12.4 Posting of Clinical Trial Consent Form  
The informed consent form will be posted on the Federal website  after the clinical trial is closed to 
recruitment,  and no later than 60 days after the last study visit by any subject , as required by the 
protocol.  
12.5 Participant and Data Confidentiality  
The ACTIV -4 Platform will have uniform policies for protecting the privacy of participants and 
maintaining confidentiality. These policies will adhere to the requirements of the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA).  
 
13 Data Handling and Record Keeping  
13.1 Data Collection and Management Responsibilities  
 
The ACTIV -4 Platform will have uniform policies for data management.  
13.2 Study Records Retention  
The ACTIV -4 Platform will have uniform policies for records retention.  
 
  Page 31 
Version: 1.2, Date: 19OCT2021   
   
13.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of 
Procedures (MOP) requirements. The noncompliance may be either on the part of the participant, 
the investigator, or the study site staff. As a result of deviations,  corrective actions are to be 
developed by the site and implemented promptly.  
 
It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report 
deviations.  
 
Protocol deviations must be reported to the local IRB per the ir guidelines. The site PI/study staff is 
responsible for knowing and adhering to their IRB requirements. Further details about the handling 
of protocol deviations will be included in the MOP.  
 
13.4 Publication and Data Sharing Policy  
The ACTIV -4 Platform will have uniform policies for publications and data sharing.  
 
14 Study Finances  
14.1 Funding Source  
National Institutes of Health . Agent specific information listed in Appe ndices as applicable.  
14.2 Costs to the Participant  
Participant health insurance may be billed for th e costs of medical care during this study since 
these expenses would have happened even if the participant  were not in the study .  If the 
participant’s  insurance does not cover these costs or the participant  does not have insurance, these 
costs will be par ticipant ’s responsibility.  
 
15 Conflict of Interest Policy  
 The ACTIV -4 Platform will have uniform policies for identifying and disclosing potential conflicts of 
interest.  
 
16 References  
 
1. Bikdeli, B., et al., COVID -19 and Thrombotic or Thromboembolic Disease:  Implications for 
Prevention, Antithrombotic Therapy, and Follow -Up: JACC State -of-the-Art Review. J Am Coll 
Cardiol, 2020. 75(23): p. 2950 -2973.  
2. Klok, F.A., et al., Incidence of thrombotic complications in critically ill ICU patients with COVID -
19. Thr omb Res, 2020. 191: p. 145 -147. 
3. Middeldorp, S., et al., Incidence of venous thromboembolism in hospitalized patients with 
COVID -19. J Thromb Haemost, 2020.  
4. Poissy, J., et al., Pulmonary Embolism in COVID -19 Patients: Awareness of an Increased 
Prevale nce. Circulation, 2020.  
5. Zhou, F., et al., Clinical course and risk factors for mortality of adult inpatients with COVID -19 in 
Wuhan, China: a retrospective cohort study. Lancet, 2020. 395(10229): p. 1054 -1062.  
 
  Page 32 
Version: 1.2, Date: 19OCT2021   
   
6. Tang, N., et al., Anticoagulant treatmen t is associated with decreased mortality in severe 
coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost, 2020. 18(5): p. 1094 -
1099.  
7. Xu J, W.L., Zhao L, et al. , Risk assessment of venous thromboembolism and bleeding in 
COVID -19 patients . BMC Pulmonary Medicine 2020.  
8. Danzi, G.B., et al., Acute pulmonary embolism and COVID -19 pneumonia: a random 
association? Eur Heart J, 2020. 41(19): p. 1858.  
9. Xie Y, W.X., Yang P, Zhang S, COVID -19 complicated by Acute Pulmonary Embolism. 
Radiology: Cardiothoracic Imaging, 2020. 2(2):e200067.  
10. Beristain -Covarrubias, N., et al., Understanding Infection -Induced Thrombosis: Lessons 
Learned From Animal Models. Front Immunol, 2019. 10: p. 2569.  
11. Clayton, T.C., M. Gaskin, and T.W. Meade, Recent respir atory infection and risk of venous 
thromboembolism: case -control study through a general practice database. Int J Epidemiol, 
2011. 40(3): p. 819 -27. 
12. Goeijenbier, M., et al., Review: Viral infections and mechanisms of thrombosis and bleeding. J 
Med Viro l, 2012. 84(10): p. 1680 -96. 
13. Smeeth, L., et al., Risk of deep vein thrombosis and pulmonary embolism after acute infection in 
a community setting. Lancet, 2006. 367(9516): p. 1075 -1079.  
14. Harms, P.W., et al., Autopsy findings in eight patients with f atal H1N1 influenza. Am J Clin 
Pathol, 2010. 134(1): p. 27 -35. 
15. Kwong, J.C., et al., Acute Myocardial Infarction after Laboratory -Confirmed Influenza Infection. 
N Engl J Med, 2018. 378(4): p. 345 -353. 
16. Wong, R.S., et al., Haematological manifestations in patients with severe acute respiratory 
syndrome: retrospective analysis. BMJ, 2003. 326(7403): p. 1358 -62. 
17. Obi, A.T., et al., Empirical systemic anticoagulation is associated with decreased venous 
thromboembolism in critically ill inf luenza A H1N1 acute respiratory distress syndrome patients. 
J Vasc Surg Venous Lymphat Disord, 2019. 7(3): p. 317 -324. 
18. Rapkiewicz, A., et al, Megakaryocytes and platelet -fibrin thrombi characterize multi -organ 
thrombosis at autopsy in 4 COVID -19: a cas e series. Lancet EClinical Medicine, 2020 ; Jun 
25;24:100434 . 
19. Oxley, T.J., et al., Large -Vessel Stroke as a Presenting Feature of Covid -19 in the Young. N 
Engl J Med, 2020. 382(20): p. e60.  
20. Al-Samkari, et al., COVID and Coagulation: Bleeding and Thr ombotic Manifestations of SARS -
CoV2 Infection. Blood, 2020. Online ahead of print.  
21.  Centers for Disease Control and Prevention. COVID -19 in Racial and Ethnic Minority 
Groups. 2020.  
22.  Price -Haywood EG, Burton J, Fort D and Seoane  L. Hospitalization and Mortality among 
Black Patients and White Patients with Covid -19. N Engl J Med . 2020.  
23. Robert W. Aldridge, Dan Lewer, Srinivasa Vittal Katikireddi, Rohini Mathur, Neha Pathak, 
Rachel Burns, Ellen B. Fragaszy, Anne M. Johnson, Dela n Devakumar, Ibrahim Abubakar and 
Haywar A. Black, Asian and Minority Ethnic groups in England are at increased risk of death 
from COVID -19: indirect standardisation of NHS mortality data [version 1; peer review: 3 
approved with reservations]. Wellcome Ope n Res . 2020;5.  
24. Niedzwiedz CL, O'Donnell CA, Jani BD, Demou E, Ho FK, Celis -Morales C, Nicholl BI, Mair FS, 
Welsh P, Sattar N, Pell JP and Katikireddi SV. Ethnic and socioeconomic differences in SARS -
CoV-2 infection: prospective cohort study using UK Bi obank. BMC Med . 2020;18:160.  
25. Millett GA, Jones AT, Benkeser D, Baral S, Mercer L, Beyrer C, Honermann B, Lankiewicz E, 
Mena L, Crowley JS, Sherwood J and Sullivan P. Assessing Differential Impacts of COVID -19 
on Black Communities. Ann Epidemiol . 2020.  
 
  Page 33 
Version: 1.2, Date: 19OCT2021   
   
26. Kamin -Mukaz D, Gergi M, Koh I, Zakai NA, Judd SE, Sholzberg M, Bauman Kreuziger L, 
Freeman K, Colovos C, Cushman M. Biomarkers of COVID -19 coagulopathy and D -dimer in a 
biracial cohort study [abstract]. Res Pract Thromb Haemost 2020;4:Suppl2.  
27. The R EMAP -CAP, ACTIV -4a, and ATTACC Investigators. Therapeutic anticoagulation with 
heparin in critically ill patients with Covid -19. N Engl J Med. DOI: 10.1056/NEJMoa2103417.  
28. The ATTACC, ACTIV -4a, and REMAP -CAP Investigators. Therapeutic anticoagulation wi th 
heparin in noncritically ill patients with Covid -19. N Engl J Med. DOI: 10.1056/NEJMoa2105911  
 
 
 
 
 
  Page 34 
Version: 1.2, Date: 19OCT2021   
   
Summary of Appendices:  
 
Appendix #  Description  Arm 
1 Master Protocol State  of Arms  N/A 
2 Definition and Determination of Outcomes  N/A 
3 (Retired)  Therapeutic -dose Anticoagulation (Arm A)  A 
4 (Retired)  Prophylactic Dose Anticoagulation (Arm B)  B 
5 ACTIV -4 Blood Sampling – proposed samples and times for 
sites participating in mechanistic studies and biorepository  N/A 
6 Additional data inclusion from other trials merged under ACTIV -4 
platform  N/A 
7 Anticoagulation  plus P2Y12 inhibitor for ICU Level of Care 
(Severe) Cohort  C 
8 (Retired)  Anticoagulation plus P2Y12 inhibitor for non-ICU Level of Care 
(Moderate ) Cohort  D 
9 Crizanlizumab   E 
10 SGLT2 Inhibitor  F 
 
 
  
 
  Page 35 
Version: 1.2, Date: 19OCT2021   
   
 
 
 
  Page 36 
Version: 1.2, Date: 19OCT2021   
   
Appendix 1: Master Protocol State  of Arms  
This appendix will be updated as  arms for each  protocol version appear below .  
 
 Version 21AUG2020  1AB: Outlined possible example scenarios for adaptive design.  Arms A 
and B included.  
 Version 01FEB 2021 : Adds Arms C and D (Appendi ces 7 and 8), implements suspension of 
Arm A in participants with ICU level of care (severe cohort ) at the time of randomization  due to 
futility,  and suspension of Arm B for non-ICU level of care participants (moderate illness ) at the 
time of randomization , due to superiority of Arm A . 
 Version 19OCT2021 : Refers to the Manual of Operations for the current state of arms and to the 
statistical analysis plan for the current analytic plan based on the curren t state of arms.  
Appendix 1.1 and  1.2 were retired . Appendix 1.3 was moved to the statistical analysis plan. 
Removed inactive appendices 3, 4, 8. The standard of care  arm does not have its own 
appendix .  
 
 
Each study agent is tested in a domain. Within the  domain a participant is randomized to study 
arms in which they receive or not receive that active agent. The Manual of Operations (MOO) 
describes the current state of arms. The MOO will be updated when any  arm is added or removed, 
when assignment to a tre atment is limited to a subset of potential participants based on interim 
analyses. When a new study test agent is added, the protocol will be amended to add the relevant 
appendix. If any arm or a subset of potential participants is stopped, the trial will continue with 
randomization to the remaining arms and/or the other subsets as long as the DSMB has indicated 
that there is no safety concern.  
 
Please refer to the Statistical Analysis Plan for the most current version of the analysis plan, taking 
into acc ount the current state of arms.  
 
All participants will receive standard of care, which includes anticoagulation as clinically indicated, 
taking into account the illness severity and any available data on effective interventions at the time 
of enrollment. Standard of care, also referred to as usual care will change over time and is 
determined locally by sites, taking into account what treatments are available in each region. 
ACTIV -4a previously tested intensity of heparin anticoagulation; recommended doses for standard 
of care may be found in the manual of operations.   
 
 
 
 
 
  Page 37 
Version: 1.2, Date: 19OCT2021   
   
Appendix 2: Definition and Determination of Outcomes  
A2.1 Approach to ascertainment and verification of outcomes  
Outcomes are assessed locally and will not be centrally adjudicated in this pragmatic trial platform, 
except as  specified in the arm-specific appendix. Outcomes should be assessed by a local 
investigator or other qualified study team member who is blinded to treatment assignment, using 
the definitions below.  
A2.2 Outcome definitions  
 
21 Day Organ -Support Free -Days  (OSFD)  
Defined as the number of days that a patient is alive and free of organ support thro ugh 2 1 days 
after trial entry. Organ support is define d by receipt of invasive or  non-invasive mechanical 
ventilation, high flow nasal oxygen, vasopressor therapy , ECMO support . If the patient dies at any 
time ( through 90  days) during the index hospital stay, they are assigned the worst possible score of 
–1. 
 Non-invasive mechanical ventilation is defined as BIPAP or CPAP when used for acute 
respiratory support (the u se of BIPAP or CPAP at night or when sleeping for sleep apnea is 
not considered organ support) . 
 High Flow Nasal Cannula Oxygen  is defined  as deliv ery of oxygen through a system that 
typically delivers oxygen at 20 to 60 liters per with a titratable FiO2.  
 Invasive mechanical ventilation is defined as positive pressure ventilation through 
endotracheal tube or tracheostomy . 
 Vasopressor support includes  infusion of any vasopressor  or inotropic medication . 
 Any patient dying in the acute hospital stay ( up to day 90 ) are assigned 2 1 Day Organ -
Support Free Days of –1. 
 If there is intervening time in which a patient is free of organ support but goes back on o rgan 
support the intervening time does not count toward the organ support free days endpoint.  
Only time before organ support and after the last use of organ support are counted as “free 
days.”  
 If a patient was discharged alive without mechanical ventilati on prior to Day 2 1, the patient is 
assumed to be free of organ support after hospital discharge for the remainder of the 2 1 
days . 
 If a patient was discharged alive on mechanical ventilation prior to Day 2 1, a call to the 
discharge facility is needed to con firm ventilation status on Day 2 1 and the last day on 
mechanical ventilation . 
 
Primary Endpoint  
Days free of organ support within 2 1 days after randomization. Organ suppor t free days (OSFD) is 
defined as  days in which patient is not on invasive or non-invasive mechanical ventilation, high flow 
nasal oxygen, or vasopressor therapy or ECMO support.  If the patient dies at any time (including 
beyond 21 days) during the index hospital stay, they are assigned the worst possible score of –1. 
To be specific about which organ support was affected, secondary outcomes  include : ventilator free 
days, vasopressor free day , and additionally renal replacement  therapy  free days .  
 
 
  Page 38 
Version: 1.2, Date: 19OCT2021   
   
Justification  for use of OSFD:  
• Pragmatic  
• Can be calculate d from  WHO ordinal scores  
• Incorporates clinically important  need for organ support but also duration of organ support  
• No additional data collection is necessary to calculate secondary outcomes of vent ilator  free 
days, renal replacement free days, and vasopressor free days to understand which organ 
support was most impacted  
• Incorporates  mortal ity as the worst possible outcome  
Secondary Endpoints  
 
Days free of organ support or RRT during index hospitalization  
Defined as the number of days that a patient is alive and free  of cardiovascular and respiratory 
organ support  and free of renal replacement therapy, during the index hospitalization  through 2 8 
days after trial entry. Organ support is defined by receipt of invasive or  non-invasive mechanical 
ventilation, high flow na sal oxygen, vasopressor therapy , ECMO support . If the patient dies at any 
time ( through 90  days) during the index hospital stay, they are assigned the worst possible score of 
–1. 
 
Deep ve in thrombosis  
Deep vein thrombosis will be diagnosed by venous ultras ound or point -of-care ultrasound (POCUS) 
or other imaging modality and documented in a note, and performed for clinical indications. A 
positive ultrasound test is defined by a noncompressible or partially noncompressible  venous 
segment and should be reported. Thrombosis may involve the cerebral venous sinus  or any venous 
bed, including the upper extremities .  Routine screening for deep vein thrombosis is not 
recommended. If deep vein thrombosis is diagnosed and treated wi thout imaging due to imaging 
availability concerns or risk of exposure to SARS CoV -2, this will be classified as probable deep 
vein thrombosis. Later imaging is preferable in these cases when possible.   
 
Pulmonary embolism  
Pulmonary embolism will be confir med by chest CT with PE protocol, pulmonary angiography or 
ventilation -perfusion scan. Events may also be defined without this imaging by the care team, as 
evidenced by, for example, “clot in transit” on echocardiogram. If PE is diagnosed and treated 
witho ut imaging due to imaging availability concerns or risk of exposure to SARS CoV -2, this will be 
classified as probable PE. Later imaging is preferable in these cases when possible.   
 
Stroke/ Peripheral  Arterial Systemic Thromboembolism   
Stroke or systemic embolis m as diagnosed by imaging (i.e.,  head CT, lower extremity CT 
angiogram) or deemed “highly -likely” by the provider based on physical examination (i.e., acute 
hemiplegia thought to be due to stroke, acute distal lower extremity hypoperfusion).  Systemi c 
thromboembolism may involve the re tinal artery, spinal cord or other vascular beds.  Classification of 
ischemic vs. other etiologies is based on neuroimaging. Venous sinus thrombosis will be included in 
the category of vascular occlusion /ischemic stroke  on the venous side.  Primary CNS hemorrhage: 
intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma, and rarely epidural 
hematoma  or spinal hematoma. Secondary hemorrhagic stroke: blood associated with an ischemic 
infarct .  
 
ICU Level of care disease state (severe illness)  
 
  Page 39 
Version: 1.2, Date: 19OCT2021   
   
Defined as receipt of cardiovascular or respiratory organ support as defined in the 21-day organ 
support free days.  ICU level of care is defined as being on  invasive or non -invasive mechanical 
ventilation, high flow nasal oxygen, or vasopressor therapy or ECMO support.  
 
Myocardial infarction  
Myocardial infarction is defined according to the universal definition of MI, which excludes 
myocardial injury  e.g., isolated elevation of cardiac troponin . MI must include rise and fall of cardiac 
troponin above the 99th percentile with at least one of the following: symptoms of acute ischemia, 
ECG changes consistent with ischemia , new/presumed new wall -motion abnormaliti es or other 
imaging evidence of MI , abnormal coronary angiography  (e.g. identification of a coronary 
thrombus) .  
 
Acute Kidney Injury  
Acute kidney injury after enrollment is defined by KDIGO criteria for Acute Kidney Injury in the 
setting of not meeting th ese criteria upon enrollment:  
     Modified  Stages : 
 Stage 2: Serum Cr 2.0 –2.9 times baseline  
 Stage 3: Serum Cr ≥ 3 .0 times baseline, OR Increase in serum creatinine to ≥  4.0mg/dl, OR 
Initiation of renal replacement therapy  
 
Renal Replacement Therapy (RRT)  
This refers to initiation of RRT during the index hospitalization, such as hemodialysis , peri toneal 
dialysis  or continuous venovenous hemofiltration.  
 
 
  
 
  Page 40 
Version: 1.2, Date: 19OCT2021   
   
WHO ordinal scale for clinical improvement  (https://www.who.int/blueprint/priority -diseases/key -
action/COVID -19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf )  
  Patient State  Score  Descr iptor 
Uninfected  0 No clinical or virological evidence of infection  
Ambulatory  1 No limitation of activities  
2 Symptomatic: Limitation of activities  
Hospitalized: Mild 
disease  3 Hospitalized; no oxygen therapy  
4 Hospitalized; oxygen by mask or nasal prongs  
Hospitalized: Severe 
disease  5 Non-invasive ventilation or high -flow oxygen  
6 Intubation & Mechanical ventilation  
7 Ventilation and additional organ support – pressors, RRT, ECMO  
Death  8 Death 
 
  Page 41 
Version: 1.2, Date: 19OCT2021   
   
Appendix  3: Therapeutic -dose Anticoagulation (Arm A)  - RETIRED  
 
 
 
  
 
  Page 42 
Version: 1.2, Date: 19OCT2021   
   
Appendix 4:  Prophylactic Dose Anticoagulation (Arm B)  - RETIRED  
  
 
  Page 43 
Version: 1.2, Date: 19OCT2021   
   
Appendix 5: ACTIV -4 Blood Sampling – proposed samples and times  for sites 
participating in mechanistic studies and biorepository  
 
The goal of the Mechanistic Studies Center and the Biorepository/Central Lab is to add significant 
value to the clinical trials by collecting high -quality blood samples for studies aimed at elucidating 
underlying disease mechanisms and insights into how th e therapy modifies these underlying 
disease processes. The plan  is to identify biomarkers of pathological mechanisms, predict 
outcomes, direct therapy, and/or identify higher -risk patient subpopulations.   
A5.1  Inpatient sampling  
 
Blood collection times  for inpatients : 
 Days 0 (time of enrollment), 3, 7 and 14 .  Samples should be obtained within 24 hours after 
the assigned time point (example: the day 3 sample should be obtained within 72 -96 hours 
after randomization ) 
 Samples should be coordinated with clinic al lab blood draws when possible.  
Standard samples to be collected & volumes at each time point:  
 Citrate plasma  
o Two 4.5 mL Citrate tubes (BD # 369714)  
 EDTA plasma  
o One 10 mL EDTA tube (BD# 366643)  
 Serum  
o One 5.0 mL Serum tube (BD # 367814)  
Note 1:  We anticip ate that some sites may not be able to collect & process all the samples and time 
points listed above. We plan to work with those sites to identify more limited time points and/or 
discard samples that could be collected, processed and sent to the bioreposi tory. 
Note 2:  We anticipate that some high -functioning sites may, in addition to the sample collections 
noted above, also participate in enhanced collections & studies, which may include:  
 Additional blood collection tubes such as:  
o HTI SCAT -144 plasma  
o Paxgene RNA whole blood  
o Cell Prep Tube (CPT)  
 Whole blood assays:  
o Viscoelastic assays (thromboelastography or thromboelastometry)  
o Platelet aggregometry  
o Whole blood genomics  
A5.2  Sample processing  
A detailed Manual of Operations (MOP) will provide instructio ns to clinical lab and research 
personnel regarding sample processing including centrifugation, processing, freezing, storing, & 
shipping samples. Also,  the following will be provided: training materials; sample processing kits 
with prelabeled  transport and/or storage vials; sample tracking software; shipping materials.  
 
  Page 44 
Version: 1.2, Date: 19OCT2021   
   
A5.3  Biorepository/Central Lab  
The Biorepository will archive biosamples from the clinical sites, and distribute them to the labs 
doing ACTIV -4 approved mechanistic studies and other research. If ACTIV -4 biosamples cannot be 
shipped to the Biorepository for some reason, the information will be captured and used to form a 
“Virtual Biorepository”, so that those samples can contribute to the mechanistic studies as well.  
 
 
 
  Page 45 
Version: 1.2, Date: 19OCT2021   
   
Appendix  6: Additional data inclusion from other trials merged  under ACTIV -4 platform  
  
There are several clinical trials that have been testing safety and efficacy of Arm A and B regimens. 
Data collected in these  trials  will be included in the data analysis under this protocol provid ed that 
the subjects consented for the  data to be shared or a waiver of consent and authorization had been 
granted by the reviewing IRB. The data will be labeled with subject ID and only include dates which 
are necessary to  assess safet y and efficacy endpoint events. All other private health information 
(PHI) will be removed. The data will be stored at the study coordinating center, University of 
Pittsburg h, in HIPAA compliant electronic system and only coordinating center staff will hav e 
access to the data.   The s tatistical analysis  plan will account for  this additional data.  
 
 Appendix 7: Background and Rationale for Arm C : P2Y12 inhibitor  for ICU Level of 
Care (Severe) Cohort  
A7.1  Background and Rationale for Arm C  
 
Analysis of therapeutic vs prophylactic dose anticoagulation in severely ill patients demonstrated 
that therapeutic dose anticoagulation was not superior, and there was a trend toward harm. 
Therefore prophylactic dose a nticoagulation is considered  standard of care for severely ill patients . 
The number of days with organ support or death over the first 21 days of the index hospitalization 
remained high despite standard of care treatment, and bleeding risk was < 2%.  Theref ore, 
additional antithrombotic and additional treatment strategies should be tested.  
 
Autopsy and clinical data highlight the potential role of platelets and their precursors in the 
pathogenesis of COVID -19.1-3  Platelets  are shed into circulation by megakaryocytes, and during 
this process, megakaryocytes distribute their transcriptome into platelets. Once in the circulation, 
platelets can respond to local and systemic conditions and induce monocyte, macrophage and 
endothe lial cell activation.4-6 Prior to COVID -19, it was described that platelet -viral interactions alter 
the platelet transcriptome and induce a proinflammatory immune mediated platelet phenotype.7 
Consistently, platelets isolated from COVID -19 patients are hyp erreactive and have an altered 
transcriptomic signature compared to disease -free controls.3  Biomarkers of platelet activity are 
elevated in COVID -19 and are associated with thrombosis and all -cause mortality even after 
multivariable adjustment. These data  suggest that platelets are activated in COVID -19 and 
represent a therapeutic target for improved clinical outcomes.  
A7.2. Eligibility Criteria for Arm C  
Note that to be eligible for randomization in a specific comparison during this adaptive trial  patient s 
are required to meet eligibility criteria for at least the standard of care  arm and one comparator arm.  
A7.2.1 Inclusion Criteria  for Arm C  
Same as the Master Protocol . 
A7.2.2 Exclusion Criteria  for Arm C    
In addition to the exclusion criteria noted in  the master protocol, arm -specific e xclusion criteria are 
as follows:  
 Moderate illness severity – non-ICU level of care at the time of randomization  (not 
receiving HFNO, NIV, IV, vasopressors or inotropes, or ECMO)  
 Contraindication to  P2Y12 inhibitor , including but not limited to  
o known bleeding within the last 30 days requiring emergency room presentation or 
hospitalization  
o known hypersensitivity to all P2Y12 inhibitors   
o known history of an inherited or active acquired bleeding disorder  
o history of intracranial hemorrhage at any time  
 Platelet count < 50  x 109/L 
 Hemoglobin < 8 g/dL  
 Requirement for ASA >162mg per day that it cannot be stopped safely  
 Requirement for P2Y12 inhibitor that cannot be stopped safely  
A7.3 Study Agents  
 
 
 Arm C consists of the combination of standard of care treatment , plus an antiplatelet agent in the 
P2Y12 inhibitor family.  
 
A7.3.1. Standard of Care Treatment  
Please refer to the manual of operations for recommended standard of care treatment .  
A7.3.2. P2Y12 In hibitor   
 
The table shows the preferred dosing for P2Y12 inhibitor treatment. Ticagrelor is the preferred 
P2Y12 inhibitor, but a ny of the following strategies are acceptable .  
Age Weight  Ticagrelor#  Prasugrel*  Clopidogrel   
<75 years  <60 kg  no load;  
60 mg  BID no load, 5 mg daily  300 mg load**,  
then 75 mg daily  ≥60 kg  30 mg load**, 10 mg daily  
≥75 years  <60 kg  no load;  
60 mg BID  not recommended  300 mg load**,  
then 75 mg daily  ≥60 kg  no load, 5 mg daily  
 
 
The preferred P2Y12 inhibitor is ticagrelor, which has a rapid onset of action without the need for a 
loading dose , unless there is a concern about drug -drug interactions (see Manual of Operations) . 
The 60 mg twice daily dose is recommended ; If ticagrelor  60 mg is not available, 90 mg dose, may 
be used.  If ticagrelor is not available or is not preferred locally, prasugrel or clopidogrel may be 
used, preferably with a loading dose , taking into account relevant drug -drug interactions (see 
Manual of Operatio ns).  
 
# if a participant will be continued on aspirin  in addition the assigned P2Y12 inhibitor , aspirin dose 
must be ≤100 mg when administered with ticagrelor  
 
* Prasugrel is NOT permitted in anyone with a prior stroke or TIA  
 
**The loading dose is prefer red because the average time to therapeutic effect with clopidogrel is 5 
days without a loading dose, and for prasugrel is 3 days without a loading dose.  A loading dose is 
not required.  
 
The first dose should be administered as soon as possible after rando mization.  
A7.3.3. Participants previously taking aspirin before randomization  
Participants taking aspirin before randomization are permitted to continue or stop aspirin therapy at 
the discretion of the treating physician.   If a patient is randomized to Arm  C and chronic ASA is 
continued per MD judgment, the recommended dose is 80-100 mg  daily; the dose MUST be ≤100 
mg daily when administered with ticagrelor.  
A7.4 Duration of treatment  
It is recommended that participants be given prophylactic -dose anticoagulation and  a P2Y12 
inhibitor daily for at least 14 days or until hospital discharge, whichever comes first. Treatment may 
 
 continue beyond 14 days at the discretion of the most responsible physician. At the time of 
treatment discontinuation, standa rd of care antithrombotic prophylaxis should be administered.   
A7.5 Discontinuation of study intervention  
Anticoagulation and/or P2Y12 inhibitor should be discontinued  if there is clinical bleeding or another 
complication sufficient to warrant cessation i n the opinion of the treating clinician.  Major bleeding, 
including death due to bleeding, is an SAE. Assigned treatment may be resumed if deemed 
appropriate by the treating clinician.   
 
Occurrence of HIT must result in the cessation of UFH or LMWH without recommencement 
regardless of treatment assignment. Use of an acceptable alternative agent is required in this 
instance as clinically indicated. Occurrence of HIT is an SAE.  If HIT occurs, the P2Y12 inhibitor may 
be continued, at the discretion of the treat ing physician, taking into account the platelet count.  
 
Study interventions can be discontinued at any time by the treating clinician if doing so is regarded 
as being in the best interests of the patient. Temporary cessation – for the shortest period of ti me 
possible  – such as to allow surgical or other procedures is not a protocol deviation.  
 
Temporary or permanent cessation of study intervention for bleeding is not a protocol deviation.  
 
A7.6 Study Schedule  
Activity  Screening/  
Enrollment  Hospital 
Duration  28 days 
and/or 
hospital 
discharge+ 
 90 days post 
randomization  
and long term 
follow -up ++ 
Eligibility      
Consent  X    
Demographic and Medical 
History  X    
Assessment of 
Inclusion/Exclusion criteria  X    
Self-reported race/ethnicity 
and sex  X    
Pregnancy Test, for 
women of childbearing 
potential  X    
Study Drug 
Administration      
Randomization  X    
Study treatment  X X¥   
Study Procedures      
Height  X    
Weight  X    
Vital signs  X X   
Concomitant medications  X X   
WHO ordinal assessment  X X X X 
 
 Quality of Life and 
Functional Status# X   X 
Outcomes assessment   X X X 
SOC Laboratory 
Assessments      
Chemistry panel  X X X  
CBC with platelet count  X X X  
Blood Group*  X    
PT, PTT if known  X X   
Anticoagulation Monitoring 
(ex,  
PTT/  Antifactor Xa level)**  X X (site -
specific)    
D-dimer***  X X X  
Troponin****  X X X  
Coagulation and 
inflammatory markers*****  X X X  
Optional Biorepository  X X   
BNP or NT-proBNP  ***** X X X  
 
*Blood group taken from hospital record or self report  if that is not available.  
** Frequency and mode (A nti-factor Xa/PTT) of testing will be based on site routine. A nti-factor Xa monitoring 
is preferred over PTT  
*** Baseline D -dimer is recommended . All values collected should be recorded.  
****Strongly recommended as part of routine care, all values collected should be recorded   
*****Optional, listed in case report form  
¥or 14 days, whichever is earlier  
#Participants may be assessed for functional status and quality of life that reflects baseline status pre-COVID 
illness and functional status and quality of life  at 90 days, when contacted to ascertain vital status . 
(Instruments detailed in the manual of operations) .  
+Assessments indicated in the table above will be ascertained at discharge, or at 28 days , whichever comes 
first. Participants must be followed for vital status until discharged from the hospital or another care facility (if 
transferred on organ support) up to 90 days. To maximize retention, participants will be contacted 
intermittently post -discharge   and that contact will be recorded in the EDC  
++Participants may be  contacted to ascertain vital status .  
A7.7 Potential Risks & Benefits  
A7.7.1 Known Potential Risks  
Participants are monitored as per standard of care  to minimize the risk of bleeding or developing 
clots.  The standard of care  plus P2Y12 inhibitor group will receive both anticoagulation and 
antiplatelet therapy and thus may be at higher risk of bleeding.  
A7.7.2 Known Potential Benefits  
Accruing  data sugg est that platelets are hyperactive in the setting of COVID -19. The platelet 
transcriptome isolated from hospitalized patients with COVID -19 is more pro -inflammatory than the 
platelet transcriptome from matched controls without COVID -19. Additionally, bioma rkers of platelet 
activity are correlated with incident thrombosis and all -cause mortality. T his arm seeks to test the  
hypothesis that th ere is a  benefit of antiplatelet therapy in addition to standard of care  for 
decreasing adverse events , including macro  and mic ro-thrombosis . This potential benefit  is 
hypothesized to  offset an increase in bleeding risk .  All participants will be closely monitored by the 
study team and any change s in antiplatelet therapy  will be discussed with the treating physicians 
 
 and/o r clinical team. There is a potential direct benefit of identifying thrombus  or bleeding more 
rapidly based on close study  monitoring. This trial will contribute to the body of generalizable 
knowledge about the antiplatelet  strategy to minimize the risk of  thrombus and adverse events  in 
patients with COVID -19.   
A7.8 Event Adjudication  
A subset of thrombotic events will be centrally adjudicated, with the proportion adjusted as needed 
based on agreement between the site and the event committee.  
A7.9 Safety A nalyses  
The safety events of importance for the standard of care  plus P2Y12 inhibitor are serious 
thrombotic events and bleeding. The rates of serious thrombotic events and mortality will be 
monitored.  The rates of serious thrombotic events  will be compare d to the standard of care  arm, as 
well as to any additional arms added to the platform trial subsequently.   For serious thrombotic 
events the DSMB will review the number of events, the event rates, and the posterior mean and 
95% credible intervals for the event rates, difference between arms, and odds -ratios between arms 
will be summarized.  
 
Major bleeding is a safety event of importance for this arm.   The rates of ISTH major bleeding, ICH 
and fatal bleeds, and mortality will be monitored.  The rates of bleeding will be compared to the 
control arm ( standard of care , no P2Y12  inhibitor ) as well as to additional a rms.  For ISTH major 
bleeding, ICH and fatal bleeds, and all -cause mortality the DSMB will review the number of events, 
the event rates, and the posterior mean and 95% credible intervals for the event rates, difference 
between arms, and odds -ratios between  arms will be summarized.  
A7.10 Statistical Analyses  
 
The primary Bayesian statistical model (see Statistical Analysis Plan ) will be used for modeling this 
arm in comparing to other arms .  The Statistical Analysis Plan  presents the interim analysis 
schedul e and adaptive decision rules . 
A7.11 References  
1. Rapkiewicz AV, Mai X. , Carsons SE, et al. Megakaryocytes and platelet -fibrin thrombi 
characterize multi -organ thrombosis at autopsy in COVID -19: A case series. EClinical 
Medicine. 2020; Jun 25;24:100434.  
2.         Barrett TJ, Lee A, Xia Y, et al. Biomarkers of Platelet Activity and Vascular Health Associate 
with Thrombosis and Mortality in Patients with COVID -19. Circ Res. 2020.  
3.         Manne BK, Denorme F, Middleton EA, et al. Platelet Gene Expression  and Function in 
COVID -19 Patients. Blood. 2020.  
4.         Nhek S, Clancy R, Lee KA, et al. Activated Platelets Induce Endothelial Cell Activation via 
an Interleukin -1beta Pathway in Systemic Lupus Erythematosus. Arterioscler Thromb Vasc 
Biol. 2017;37(4): 707-716. 
5.         Campbell RA, Schwertz H, Hottz ED, et al. Human megakaryocytes possess intrinsic 
antiviral immunity through regulated induction of IFITM3. Blood. 2019;133(19):2013 -2026.  
6.         Barrett TJ, Schlegel M, Zhou F, et al. Platelet regulat ion of myeloid suppressor of cytokine 
signaling 3 accelerates atherosclerosis. Sci Transl Med. 2019;11(517).  
7.         Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front 
Immunol. 2014;5:649.  
8.  Gould MK, Garcia DA, Wren SM, et al.  Prevention of VTE in nonorthopedic surgical patients: 
antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest 
 
 Physicians evidence -based clinical practice guidelines . Chest . 2012; 141(2 suppl ):e227S -
277S.  
9. Garcia D, Baglin T, Weitz J, et al . Parenteral Anticoagulants: Antithrombotic Therapy and 
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence -Based 
Clinical Practice Guidelines . Chest 2012 Feb ;141 
   
 
 Appendix 8: Anticoagulation , Plus P2Y12 Inhibitor (Arm D)  for non -ICU Level of Care 
(Moderate) Cohort – RETIRED  
 
Appendix 9: Standard of Care Plus Crizanlizumab (Arm E)  
A9.1  Background and Rationale for Arm E  
 
Microvascular inflammation and thrombosis play a central role in the pa thophysiology of COVID -19 
and its clinical sequela, and growing data implicate endothelial damage as a major component in 
COVID -19 disease[1].  Release of both P -selectin and Von Willebrand Factor (VWF) from 
endothelial granules occurs in the setting of en dothelial cell activation and has been related to 
severity of disease in COVID -19[2-4].  P -selectin mediates leukocyte rolling and anchors VWF to 
the vessel wall, where VWF then interacts with platelets.  Thus, P -selectin may play a role in 
leukocytes and platelet adherence to endothelial cells and obstruction of the lung microvasculature, 
which appears common in severe COVID -19 disease. As resting endothelial cells and platelets do 
not express P -selectin, the interaction between P -selectin expressed on the  cell surface and its 
ligand may be an initial step in vascular inflammation and thrombosis following endothelial injury or 
activation.  P -selectin on the surface of platelets also plays a role in platelet adherence and 
thrombosis.   
 
Crizanlizumab is an I gG2 kappa humanized monoclonal antibody that binds to P -selectin with high 
affinity, blocking the interaction between P -selectin and its ligand. The SUSTAIN clinical trial 
showed that crizanlizumab reduced vaso -occlusive events in patients with sickle cell  disease 
(SCD), a process that involves endothelial release of P -selectin and vaso -occlusion[5].  
Crizanlizumab was well tolerated and is FDA approved to reduce the frequency of vaso -occlusive 
crisis in patients 16 and older with SCD.   
 
Crizanlizumab was tested in a randomized controlled pilot trial in patients with COVID -19 
([STUDY_ID_REMOVED]). In 42 patients who were randomized, received drug, and had evaluable data for 
follow -up, crizanlizumab resulted in a substantial and sustained reduction in soluble P -selectin.  
Crizanlizumab also appeared to be related to biochemical changes in markers of thrombosis 
suggestive of induction of fibrinolysis. No safety signals emerged.  
 
Pharmacology:   Crizanlizumab is administered 5.0 mg/kg intravenously over 30 min in pati ents with 
SCD.  Crizanlizumab is 100% bioavailable.  The median time to reach maximum concentration is 
1.6 h.  The volume of distribution is 4.3 L after a single dose in healthy volunteers.  The half -life is 
10.6 d. The route of elimination is not through the liver or kidneys.  
 
Safety:   Crizanlizumab is generally well -tolerated.  In a randomized, double -blind, placebo -
controlled trial (SUSTAIN) of 198 patients, serious adverse events were reported in 55 patients, 
including 17 patients in the placebo group, 21 in the low dose crizanlizumab group, and 17 in the 
high dose crizanlizumab group.  The serious adverse events that occurred in ≥2 patients in either 
active treatment group and at a higher frequency than in the placebo group were pyrexia and 
influenza. A  total of 5 patients died during the trial, including 2 patients in the high -dose 
crizanlizumab group (1 patient from the acute chest syndrome, and 1 from endocarditis and sepsis), 
1 in the low -dose crizanlizumab group (from the acute chest syndrome, aspir ation, respiratory 
failure, and progressive vascular congestion), and 2 in the placebo group (1 from right ventricular 
failure, and 1 from vaso -occlusive crisis, ischemic stroke, coma, sepsis, and venous thrombosis of 
the right lower limb). Three, single -occurrence adverse events considered to be both serious and 
 
 life-threatening, but that did not result in death included: sepsis (in the placebo group), anemia (in 
the low -dose crizanlizumab group), and intracranial hemorrhage (in the low -dose crizanlizumab 
group). The patient with intracranial hemorrhage was being treated with ketorolac at the time of the 
event, which is associated with an increased risk of hemorrhagic stroke. No other clinically 
significant bleeding events were observed in the trial. Advers e events that occurred in ≥10% of 
patients in either active -treatment group were headache, back pain, nausea, arthralgia, pain in 
upper and lower limbs, urinary tract infection, upper respiratory tract infection, pyrexia, diarrhea, 
musculoskeletal pain, pr uritus, vomiting, and chest pain[5]. Adverse events that occurred in ≥10% 
of patients in either active treatment group and at a frequency that was at least twice as high as that 
in the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain[5].  
 
Infusion -related reactions:  Administration of monoclonal antibodies can be associated with 
infusion -related reactions (IRR). In the SUSTAIN trial of crizanlizumab to prevent vaso -occlusive 
events in patients with SCD, IRRs were more frequent in the 5 mg/kg arm (23 patients, 34.8%) than 
placebo arm (13 patients, 21.0%). However, only 1 event, nausea, was reported in at least 10% of 
patients: 10.6% vs. 1.6% patients in 5 mg/kg vs. placebo arm, respectively. Except for nausea, 
none of the events wer e reported with an absolute difference of more than 5% in the crizanlizumab 
5 mg/kg arm vs. placebo. A review of potential IRR events revealed few cases supportive of typical 
IRRs. None of these AEs were suggestive of severe allergic or anaphylactic reacti ons. Most 
patients continued their treatments without need for premedication[5].  
A9.2 Eligibility Criteria for Arm E  
A9.2.1 Inclusion Criteria for Arm E  
 
Inclusion criteria contained in the master protocol in addition to the following:  
 
Moderate illness severity – defined as non -ICU level of care at the time of randomization (not 
receiving high flow nasal oxygen (HFNO), non -invasive ventilation (NIV), invasive ventilation (IV), 
vasopressors or inotropes, or extracorporeal membrane oxygenation (ECMO)  
OR  
Severe illness severity – defined as ICU level of care at the time of randomization (receiving HFNO, 
NIV, IV, vasopressors or inotropes, or ECMO)  
 
For moderate illness severity, participants are required to meet one or more of the following risk 
criteria:  
1. Age ≥ 65 years or 
2. ≥2 of the following:  
 O2 supplementation > 2 liters per minute  
 BMI ≥ 35 
 GFR ≤ 60  
 History of Type 2 diabetes   
 History  of heart failure (regardless  of ejection fraction)  
 D dimer ≥ 2x the site’s upper limit of normal (ULN)  
 Troponin ≥ 2x the site’s ULN  
 BNP≥100 pg/mL  or NT -proBNP≥300 pg/mL  
 CRP ≥50 mg/L  
A9.2.2 Exclusion Criteria for Arm E   
 Exclusion criteria contained in the master protocol, and  
 
  Any condition that, in the opinion of the investigator, precludes the use of crizanlizumab 
such as uncontrolled bleeding or severe anemia (hemoglobin<4 g/dL)   
 Open label treatment with crizanlizumab within the past three months  
A9.3 Study Agent  
 
Arm E consists of the combination of standard of care plus crizanlizumab. Please refer to the 
manual of operations for recommended standard of care, including standard of care antithrombotic 
therapy for moderate and severe illness severity, respectively.  
 
A9.3.1. Crizanlizumab  
Crizanlizumab is a monoclonal IgG2 kappa humanized antibody to P -selectin. In patients 
randomized to receive crizanlizumab, the drug will be administered intravenously as a fixed -dose, 
one-time infusion of 5.0mg/kg over 30 minutes.  
 
In the pivotal SUSTAIN trial[5] of crizanlizumab for the prevention of vaso -occlusive events in 
patients with SCD, there were a total of 198 patients, of which 67 patients received high -dose 
crizanlizumab at a dose of 5mg/kg administered every 2 weeks, 66  patients received low -dose 
crizanlizumab at a dose of 2.5mg/kg administered every two weeks, and 65 patients received 
placebo. High -dose crizanlizumab was found to be effective in this trial. The FDA has subsequently 
approved the use of crizanlizumab 5.0 mg/kg every two weeks to prevent vaso -occlusive disease in 
patients with SCD.  
 
In a randomized controlled pilot trial of crizanlizumab in COVID -19 ([STUDY_ID_REMOVED]), patients were 
randomly assigned in a 1:1 ratio to receive double -blind treatment with one intr avenous dose of 
crizanlizumab 5.0 mg/kg or placebo as a single dose. A total of 54 patients fulfilled study entry 
criteria, and were randomized to receive crizanlizumab (n = 27) or placebo (n = 27). In total, 25 
patients received crizanlizumab, and 25 pati ents received placebo, and the primary endpoint was 
available in 22 patients in the crizanlizumab group and 20 in the placebo group. Crizanlizumab 
infused as a single intravenous dose of 5.0 mg/kg was associated with 89% (95% Confidence 
Interval:  93% to 8 0%) reduction in P -selectin levels relative to baseline by day 3 or before 
discharge.  
 
Pharmacology :  Crizanlizumab is administered intravenously and is 100% bioavailable. The median 
time to reach maximum serum concentration (Tmax) was 1.6 hours at steady -state following an 
intravenous administration of 5 mg/kg over 30 minutes in SCD patients. Distribution is typical of 
endogenous human antibodies within the vascular and extracellular spaces. The volume of 
distribution at steady state (Vz) was 4.3 L after a single 5 mg/kg intravenous infusion in healthy 
volunteers. Antibodies are predominately eliminated via proteolysis by lysosomal enzymes into 
small peptides and amino acids. In healthy volunteers, the mean terminal elimination half -life (T1/2) 
was 10.6 da ys, and the mean clearance was 11.7 mL/hr at a dose level of 5 mg/kg. In patients with 
SCD, the mean apparent T1/2 during dosing interval was 7.6 days, and the estimated clearance 
was 17.2 mL/hr. There was no indication of accelerated clearance or time -dependent change in the 
PK properties of crizanlizumab following repeated administration. No dedicated studies have been 
conducted to evaluate specific pathways of crizanlizumab excretion or to investigate the 
pharmacokinetics PK of crizanlizumab in patients with renal or hepatic impairment since antibodies 
are not metabolized by cytochrome P450 enzymes, and the kidneys or liver are not a major organ 
for antibody metabolism or excretion.  
 
 
 Interactions between crizanlizumab and other medicinal products have not  been investigated in  
dedicated studies.  Monoclonal antibodies are not metabolized by cytochrome P450 (CYP450) 
enzymes. Therefore, medicinal products that are inhibitors or inducers of CYP450 are not expected 
to affect the PK of crizanlizumab. Concomitant  medications, including 
Hydroxyurea/Hydroxycarbamide, did not affect crizanlizumab PK in patients with SCD in clinical 
studies.  
 
Based on the data generated to date, crizanlizumab does not have a clinically relevant effect on the 
QT interval.  The relation ship between crizanlizumab exposure and changes in QTc from baseline 
(ΔQTc) was assessed using a linear mixed -effects model in pooled data from 66 healthy subjects 
for whom at least 1 valid time -matched PK -ECG measurement was available.  The model estimate d 
mean ΔQTc at steady -state Cmax observed in SCD patients was 0.23 ms (90% CI: -0.72, 1.20 ms). 
This effect is not clinically relevant since the upper 90% CI is well below the regulatory threshold of 
change in QTc interval of 10 ms.  
 
Storage: Crizanlizumab  must be stored at a temperature between 2°C to 8°C (36°F to 46°F) in the 
original carton. Crizanlizumab must be stored separately from ordinary hospital stocks and must be 
stored in a securely locked area accessible only to authorized trial personnel unti l dispensed. The 
temperature must be monitored and documented on the appropriate form for the entire time that the 
investigational product is at the trial site. If the storage temperature deviates from the permitted 
range, crizanlizumab must not be adminis tered, and the Site Investigator or responsible person 
should contact the DCC for further instructions.  
 
Administration:  The pharmacist or designated personnel will prepare individual doses of 
crizanlizumab for subjects on a milligram per kilogram basis (a t a dose of 5 mg/kg)  in a 100 mL 
infusion bag according to the guidance in the prescribing information for crizanlizumab. 
Crizanlizumab will be administered over 30 minutes by intravenous infusion as soon as possible 
after randomization.  
A9.3.3 Participan ts receiving additional monoclonal antibody treatment(s)  
Co-administration or prior administration of a monoclonal antibody as part of standard of care or as 
part of another investigational treatment is permitted.  However, efforts should be made to avoid  
intravenous monoclonal antibody therapy in the 36 hours prior to and 36 hours after crizanlizumab 
infusion unless it is felt to be medically necessary.  
A9.3.4 Participants who become pregnant within 90 days of study treatment  
Sexually active men and women  of childbearing potential must use highly effective form(s) of birth 
control (contraception) for at least 15 weeks (105 days) after crizanlizumab infusion. Pregnancy 
status in female participants of childbearing potential and partners of sexually active m ale 
participants will be obtained at the 90 -day follow -up assessment. If pregnancy is reported, site 
investigators will report a serious adverse event and obtain verbal consent from participants to 
obtain contact information for the participant’s treating physician/obstetrician for further follow up. If 
consent is obtained, the study team may provide details to the treating physician/obstetrician 
(including DOB) to help identify the patient of interest. Novartis safety team may contact treating 
physicians t o obtain further information on pregnancy outcomes using a study assigned participant 
ID that will be provided to both parties (Novartis and treating physician.) Participant direct identifiers 
will not be provided to the drug supplier, Novartis.    
 
 A9.4 Du ration of treatment  
Crizanlizumab is administered as a single, one -time infusion, and duration of action is known to 
extend up to one month in studies of patients with SCD.  
A9.5 Discontinuation of study intervention  
Discontinuation during study infusion is based on unexpected or other adverse events during 
infusion. The overall duration of infusion is less than 30 minutes. If study drug is discontinued due to 
an unexpected or adverse event during infusion, re -initiation will not be allowed.  
 
 
A9.6 Study Schedule  
Activity  Screening/  
Enrollment  Hospital 
Duration  28 days or 
hospital 
discharge+ 
 90 days post 
randomization 
and long term 
follow -up ++ 
Eligibility      
Consent  X    
Demographic and Medical History  X    
Assessment of Inclusion/Exclusion 
criteria  X    
Self-reported race/ethnicity and 
sex X    
Pregnancy Test, for women of 
childbearing potential  X    
Study Drug Administration      
Randomization  X    
Study treatment (infusion)  X X   
Study Procedures      
Height  X    
Weight  X    
Vital signs  X X   
Concomitant medications  X X   
WHO ordinal assessment  X X X X 
Quality of Life and Functional 
Status# X   X 
Outcomes assessment   X X X 
Pregnancy Outcomes     X 
SOC Laboratory Assessments      
Chemistry panel  X X X  
CBC with platelet count  X X X  
Blood Group*  X    
PT, PTT if known  X X   
D-dimer***  X X X  
Troponin****  X X X  
Coagulation and inflammatory 
markers*****  X X X  
Optional Biorepository  X X   
 
 BNP or NT-proBNP ***** X X  X  
 
*Blood group taken from hospital record or self -report if that is not available.  
** Frequency and mode (Anti -factor Xa/PTT) of testing will be based on site routine. Anti -factor Xa monitoring 
is preferred over PTT  
*** Baseline D -dimer is recommended. All values collected should be recorded.  
****Strongly recommended as part of routine care, all values collected should be recorded  
*****Optional, listed in case report form  
#Participants may be assessed for functional status and quality of life that reflects baseline status pre -COVID 
illness and  functional status and quality of life at 90 days when contacted to ascertain vital status. 
(Instruments detailed in the manual of operations).  
+Assessments indicated in the table above will be ascertained at discharge or 28 days, whichever comes first. 
Participants must be followed for vital status until discharged from the hospital or another care facility (if 
transferred on organ support) for up to 90 days. To maximize retention, participants will be contacted 
intermittently post -discharge  and that con tact will be recorded in the EDC  
++Participants will be contacted to ascertain pregnancy and vital status . Pregnancy tests will not be 
administered.   
 
 
A9.7 Potential Risks & Benefits  
A9.7.1 Known and Potential Risks  
Participants are monitored as per standard of care to minimize the risk of bleeding or developing 
clots. The crizanlizumab group may receive anticoagulants or additional antithrombotic therapies as 
part of standard care and thus could be at higher risk of bleeding.  
 
Administration of monoc lonal antibodies can be associated with infusion -related reactions (IRR). In 
the SUSTAIN trial of crizanlizumab to prevent vaso -occlusive events in patients with SCD, IRRs 
were more frequent in the 5 mg/kg arm (23 patients, 34.8%) than placebo arm (13 pati ents, 21.0%). 
However, only 1 event, nausea, was reported in at least 10% of patients: 10.6% vs. 1.6% patients in 
5 mg/kg vs. placebo arm, respectively. Except for nausea, none of the events were reported with an 
absolute difference of more than 5% in the crizanlizumab 5 mg/kg arm vs. placebo. A review of 
potential IRR events revealed few cases supportive of typical IRRs. None of these AEs were 
suggestive of severe allergic or anaphylactic reactions. Most patients continued their treatments 
without need for  premedication[5].  
 
Interactions between crizanlizumab and other medicinal products have not been investigated in  
dedicated studies.  Monoclonal antibodies are not metabolized by cytochrome P450 (CYP450) 
enzymes. Therefore, medicinal products that are inh ibitors or inducers of CYP450 are not expected 
to affect the PK of crizanlizumab. Concomitant medications, including 
Hydroxyurea/Hydroxycarbamide, did not affect crizanlizumab PK in patients with SCD in clinical 
studies.  
 
Based on the data generated to dat e, crizanlizumab does not have a clinically relevant effect on the 
QT interval.  The relationship between crizanlizumab exposure and changes in QTc from baseline 
(ΔQTc) was assessed using a linear mixed -effect model in pooled data from 66 healthy subjects for 
whom at least 1 valid time -matched PK -ECG measurement was available.  The model estimated 
mean ΔQTc at steady -state Cmax observed in SCD patients was 0.23 ms (90% CI: -0.72, 1.20 ms). 
This effect is not clinically relevant since the upper 90% CI is wel l below the regulatory threshold of 
change in QTc interval of 10 ms.  
 
 
 There is no evidence that crizanlizumab causes a reduction in circulating platelets or has a pro -
aggregant effect in vivo. In pooled data from SUSTAIN and the single -arm CSEG101A2202 tri al, 
111 patients with SCD received the 5mg/kg dose of crizanlizumab, of which 15 patients (13.5%) 
had any thrombocytopenia, and 3 patients (2.7%) had Grade 3 or 4 thrombocytopenia. These rates 
of thrombocytopenia were similar to that of SCD patients given placebo. Among 28 healthy 
volunteers dosed with 5mg/kg of crizanlizumab, one patient had thrombocytopenia.  
 
Crizanlizumab can cause lab testing artifacts in automated platelet counts.  Platelet counts in blood 
drawn from patients can show false low platel et levels due to platelet clumping in the test tube.  To 
mitigate the potential for this laboratory test interference, it is recommended to run the respective 
test as soon as possible (within 4 hours of blood collection) or use citrate tubes. When needed, 
platelet counts can be estimated via a peripheral blood smear.  
 
P-selectin plays a role in the initial recruitment of leukocytes to the site of injury during  
inflammation. Therefore, crizanlizumab could potentially be associated with an increased risk for 
infections. In the SUSTAIN trial, urinary tract infection occurred in 9 (14%) of patients allocated to 
the high dose crizanlizumab group, 7 (11%) patients allocated to the low dose crizanlizumab group, 
and 7 (11%) patients allocated to placebo. Upper respi ratory tract infection rates were similar 
across groups, occurring in 7 (11%) of patients allocated to the high dose crizanlizumab group, 7 
(11%) patients allocated to the low dose crizanlizumab group, and 6 (10%) patients allocated to 
placebo. In pooled d ata from SUSTAIN and the single -arm CSEG101A2202 trial, a total of 111 
patients received the 5mg/kg dose of crizanlizumab, of which 13 (11.7%) had upper respiratory tract 
infection. Lower respiratory tract infection occurred in 1 (0.9%) patient. Among heal thy controls in a 
Phase I study to the PK/PD of crizanlizumab, viral upper respiratory tract infection occurred in 3 
subjects (10.7%) who received crizanlizumab at a higher dose of 7.5 mg/kg. In summary, no 
increased frequency or severity of infections has  been observed in clinical studies with 
crizanlizumab to date.  
A9.7.2 Known Potential Benefits  
A substantial and growing body of evidence suggests that endothelial injury is widespread and may 
link inflammation and thrombosis in severe COVID -19 disease.   Endothelial granules contain VWF 
and P -selectin, which are released by exocytosis in response to endothelial injury. Following 
release, P -selectin is displayed on the surface of endothelial cells and serves to anchor VWF 
multimers to the cell surface. The se mechanisms may contribute to the micro and macro thrombotic 
complications common in severe disease.  
 
This arm seeks to test the hypothesis that the P -selectin inhibitor crizanlizumab, in addition to 
standard of care, would decrease adverse outcomes, in cluding death, organ support free days, and 
micro and macro thrombosis. There is a potential benefit of identifying thrombus or bleeding more 
rapidly based on close study monitoring. This trial will contribute to the body of generalizable 
knowledge about t his therapy and the role of P -selectin in COVID -19 disease.  
 
 
A9.8  Event Adjudication  
A subset of thrombotic events will be centrally adjudicated, with the proportion adjusted as needed 
based on agreement between the site and the event committee.  
 
 A9.9  Sa fety Analyses  
The rate of infusion -related SAEs will be monitored. The rates of ISTH major bleeding, ICH and 
fatal bleeds, major thrombotic events, and mortality will be monitored in comparison to the standard 
of care arm as well as to any additional arms added to the platform trial.  The DSMB will review the 
number of events, the event rates, and the posterior mean and 95% credible intervals for the event 
rates, difference between arms, and odds -ratios between arms will be summarized.  
A9.10 Statistical Ana lyses  
This arm will be compared to the Crizanlizumab standard of care arm.  Patients eligible for 
Crizanlizumab will be randomized to either Crizanlizumab or no Crizanlizumab.  These same 
patients may be randomized to other therapies within this master pro tocol.  The comparison will be 
between those randomized to Crizanlizumab vs those randomized to no Crizanlizumab.   
 
The primary Bayesian statistical model (see Statistical Analysis Plan) will be used for modeling the 
effect of Crizanlizumab in comparison to no Crizanlizumab with the following exceptions:  
1. The model will contain a main effect for each other therapy that was randomized for each 
patient.  
2. Site will not be included in the primary analysis model, but instead the country for the site 
will be inclu ded. 
 
The Statistical Analysis Plan presents the interim analysis schedule and adaptive decision rules.  
 
The primary analysis for Crizanlizumab will be restricted to only patients in the intent -to-treat for 
Crizanlizumab.  This group are those patients tha t have been randomized to potentially receive 
Crizanlizumab.  No patients that were not randomized to yes/no for Crizanlizumab will be used in 
the primary analysis for Crizanlizumab.  
A9.11 Safety Reporting  
The following safety information should be report ed: 
 
● Serious Adverse Events (SAEs), excluding study endpoints, in patients exposed to 
crizanlizumab should be reported within 14 calendar days of becoming aware of it, including 
those which may have been the reason for the patient to discontinue infusion.  
● Any other relevant safety information listed below in patients exposed to crizanlizumab 
should be reported within 14 calendar days of becoming aware of it:  
o overdose (with or without clinical symptoms),  
o intentional drug misuse/abuse (with or without clinica l symptoms),  
o medication errors (including maladministration, dispensing or prescribing errors, 
with or without clinical symptoms),  
o suspected drug -drug or drug -food interaction (with or without clinical symptoms)  
o Pregnancy within 90 days of receiving criza nlizumab   
A9.12 References  
1. Libby, P. and T. Luscher, COVID -19 is, in the end, an endothelial disease. Eur Heart J, 
2020. 41(32): p. 3038 -3044.  
2. Lowenstein, C.J. and S.D. Solomon, Severe COVID -19 Is a Microvascular Disease. 
Circulation, 2020. 142(17):  p. 1609 -1611.  
3. Goshua, G.,  et al., Endotheliopathy in COVID -19-associated coagulopathy: evidence from a 
single -centre, cross -sectional study. Lancet Haematol, 2020. 7(8): p. e575 -e582.  
 
 4. Barrett, T.J., et al., Platelet and Vascular Biomarkers Associate  With Thrombosis and Death 
in Coronavirus Disease. Circ Res, 2020. 127(7): p. 945 -947. 
5. Ataga, K.I., et al., Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N 
Engl J Med, 2017. 376(5): p. 429 -439. 
  
 
 Appendix 10: Standard  of care  plus SGLT2 inhibitor  
A10.1  Background and Rationale for Arm F   
 
Patients who are hospitali zed with coronavirus disease 2019 (Covid -19) remain  at high risk for 
multi-organ failure and death . Given the dearth of efficacious therapies that reduce the risk of major 
clinical events,  there is a large unmet need for additional treatment options .  
 
Sodium –glucose cotransporter 2 (SGLT2) inhibitors  provide organ protection and reduce 
cardiovascular and kidney events in large trials of predominantly ambulatory patie nts with type 2 
diabetes, cardiovascular and/or kidney disease  (1-3). Although the mechanisms underlying these 
benefits remain a subject of investigation, prior studies have shown that SGLT2 inhibitors favorably 
affect a number of pathways that are dysregu lated in the setting of acute illness (including Covid -
19) such as inhibition of glycolysis (a pathway that can be used by respiratory pathogens) and 
stimulation of lipolysis, reduction in oxidative stress and inflammation, as well as improved 
endothelial function and oxygen carrying capacity , and protection against capillary leak (4 -11). 
These effects may help prevent multi -organ damage and improve recovery in Covid -19.  
 
A previous large trial of SGLT2 inhibitor dapagliflozin in patients with chronic kidn ey disease 
demonstrated significant reduction in all -cause death, driven predominantly via lower rates of non -
cardiovascular (and specifically infection -related) death (12). Large observational studies have also 
suggested lower risk of major clinical event s in patients hospitalized with Covid -19 that were on 
background SGLT2 inhibitor therapy (13).  
 
The effectiveness and safety of SGLT2 inhibitor dapagliflozin was investigated in the Dapagliflozin 
in Respiratory Failure in Patients with Covid -19 (DARE -19) which randomized 1250 patients  with 
cardiometabolic risk factors hospitali zed with Covid -19 across 7 countries and 95 sites to either 
dapagliflozin  10 mg daily or placebo for 30 days (14). Treatment was continued in case of patients’ 
clinical status deterioration requirining ICU level care, and regardless of hospital discharge. Fewer 
patients treated with dapagliflozin experienced the composite endpo int of respiratory, 
cardiovascular or kidney failure, or death from any cause at 30 days (HR 0.80, 95% CI 0.58-1.10); 
although this was not statistically significant, the trial only accrued 156 of the initially planned 380 
events (due to a large decline in  event rates during the course of the trial) and therefore did not 
have sufficient power for this endpoint. Importantly, the results were directionally favorable to 
dapagliflozin across each component of this composite outcome, including death from any cau se 
(HR 0.77, 95% CI 0.52 – 1.16).  
 
Dapagliflozin was well tolerated, with fewer serious adverse events than placebo.   
 
Dapagliflozin  is considered as the preferred SGLT2 inhibitor for this arm of the trial, given the 
following considerations: 1) it is the only agent in the class for which the efficacy and safety data 
from randomized controlled trials in patients hospitalized with Covid -19 is available 2) it has a well 
established safety profile across various patient populations and 3) extensive clinical experience 
and broad availability in more than 90 countries. However, because the potential benefits of SGLT2i 
are expected to represe nt a class effect, other SGLT2 inhibitors (such as empagliflozin) can be 
used if dapagliflozin is not available at the participating hospital site.  
 
Pharmacology:   Dapagliflozin is a highly selective SGLT2 inhibitor that is administered at the dose 
of 10 m g once daily, via enteral route. Dapagliflozin  is 78% bioavailable.  The median time to reach 
 
 maximum concentration is 2 h. The half -life is 12.9 h. The route of elimination is via kidneys  and GI 
tract. 
 
Empagliflozin is a highly selective SGLT2 inhibitor that is administered at the dose of 10 mg once 
daily, via oral route. The median time to reach maximum concentration is 1.5 h. The half -life is 12.4 
h. The route of elimination is via kidneys  and GI tract . 
 
Safety:   Dapagliflozin has been used extensively in clinical practice (predominantly for management 
of Type 2 diabetes and heart failure) since its approval (in European Union) in 2011, has been 
evaluated in tens of thousands of patients in clinical trials across Type 2 diabetes, heart failure and 
chroni c kidney disease, and prescribed to millions of patients (with marketing authorization in more 
than 90 countries).  
 
The safety of dapagliflozin in patients hospitalized with Covid -19 was specifically evaluated in the 
DARE -19 Trial, where it was well toler ated. Specifically, fewer patients treated with dapagliflozin as 
compared with placebo experienced serious adverse events (including fatal SAEs), adverse events 
leading to discontinuation of study medication, and adverse events of acute kidney injury. Due to 
potential concerns regarding the risk of diabetic ketoacidosis in patients treated with dapagliflozin, a 
proactive surveillance program was used in the DARE -19 trial, with mandatory daily monitoring of 
acid-base status among those with Type 2 diabetes ( 15). Only 2 cases of DKA were observed in 
patients treated with dapagliflozin (versus 0 with placebo). Both of these occurred in patients with 
Type 2 diabetes, were non -severe, and resolved rapidly after discontinuation of study medication.  
 
A10.2. Eligibi lity Criteria for Arm F  
A10.2.1 Inclusion Criteria for Arm F  
 
Inclusion criteria contained in the master protocol in addition to the following:  
 
Moderate illness severity – defined as non-ICU level of care at the time of randomization (not 
receiving high flow nasal oxygen ( HFNO ), non-invasive ventilation ( NIV), invasive ventilation ( IV), 
vasopressors or inotropes, or extracorporeal membrane oxygenation ( ECMO) ) 
OR  
Severe illness severity – defined as ICU level of care at the time of randomization (receiving HFNO, 
NIV, IV, vasopressors or inotropes, or ECMO)  
 
For moderate illness severity, participants are required to meet one or more of the following risk 
criteria:  
1. Age ≥ 65 years or 
2. ≥2 of the following:  
 O2 supplementation > 2 liters per minute  
 BMI ≥ 35 
 GFR ≤ 60  
 History of Type 2 diabetes   
 History of heart failure  (regardless of ejection fraction)  
 D dimer ≥ 2 x the site’s upper limit of normal  (ULN)  
 Troponin ≥ 2x the site’s ULN  
 BNP≥ 100 pg/mL  or NT-proBNP≥ 300 pg/mL  
 CRP ≥50 mg/L  
 
 A10.2.2 Exclusion Criteria for Arm F    
In addition to the exclusion criteria noted in the master protocol, arm -specific exclusion criteria are 
as follows:  
 Known hypersensitivity to any SGLT2 inhibitors  
 Type 1 diabetes  
 History of diabetic ketoacidosis  
 eGFR <2 0 and/or requirement for renal replacement therapy  
 Open label treatment with any SGLT2 inhibitor  
 
A10.3 Study Agents  
 
Arm F consists of the combination of standard of care plus an SGLT2 inhibitor (dapagliflozin 
preferred). Please refer to the manual of ope rations for recommended standard of care, including 
standard of care antithrombotic therapy for moderate and severe illness severity, respectively.  
A10.3.2. SGLT2 inhibitors  
 
Dapagliflozin  (preferred SGLT2 inhibitor for this arm) is a highly selective sodium glucose 
cotransporter 2 (SGLT2) inhibitor . In patients randomized to receive SGLT2 inhibitors , dapagliflozin 
(or empagliflozin) will be administered orally  at 10 mg once daily . If patie nt requires intubation and 
mechanical ventilation, or cannot receive oral medications for another reason, the tablet can be 
crushed and flushed down the feeding tube . 
 
In the international, multi -center, double -blind, placebo -controlled DARE -19 trial of da pagliflozin for 
prevention of organ failure or death in patients hospitalized with Covid -19, fewer patients treated 
with dapagliflozin experienced the composite endpoint of respiratory, cardiovascular or kidney 
failure, or death from any cause ((HR 0.80, 9 5% CI 0.58-1.10); although this was not statistically 
significant due to fewer accrued events than originally anticipated. The results were directionally 
favorable to dapagliflozin as compared with placebo for each component of this composite outcome 
(resp iratory, cardiovascular, kidney decompensation, and death from any cause). Dapagliflozin was 
well tolerated, with fewer serious adverse events than placebo . 
  
Dapagliflozin is considered as the preferred SGLT2 inhibitor for this arm of the trial, given the  
following considerations: 1) it is the only agent in the class for which the efficacy and safety data 
from randomized controlled trials in patients hospitalized with Covid -19 is available 2) it has a well 
established safety profile across various patient populations and 3) extensive clinical experience 
and broad availability in more than 90 countries. However, because the potential benefits of SGLT2i 
are expected to represent a class effect, other SGLT2 inhibitors (such as empagliflozin) can be 
used if dap agliflozin is not available at the participating hospital site.  
 
 
Pharmacology :  The main action of SGLT2 inhibitors is enhanced excretion of glucose and sodium 
via inhibition of sodium glucose cotransporter 2 in the proximal tubule. Dapagliflozin  is admin istered 
enterally , and is 78% bioavailable. The median time to reach maximum serum concentration (Tmax ) 
is 2 hours. The mean terminal elimination half -life (T1/2) is 12.9 hours . Dapagliflozin is 
predominantly excreted via kidneys (75%) and GI tract (21%). Empagliflozin is a highly selective 
SGLT2 inhibitor that is administered at the dose of 10 mg once daily, via enteral route. The median 
time to reach maximum concentration is 1.5 h. The half -life is 12.4 h. The route of elimination is via 
kidneys  (54%) and GI tract (41%) . 
 
  
 
There are no meaningful drug -drug interactions reported with dapagliflozin (or empagliflozin), with 
exception of enhanced glucose -lowering when co -administered with insulin or insulin 
secretagogues.  
 
 
Storage: SGLT2 inhibitors will be stored per local pharmacy policies and procedures.  
 
Administration:  Dapagliflozin (or empagliflozin) will be administered orally (or via feeding tube, if 
applicable) at the dose of 10 mg daily . The first dose should be administered as soon as possi ble 
after randomization.  
 
A10.3.3 Participants receiving additional Covid -19 therapies   
Co-administration or prior administration of other Covid -19 therapies (other than an SGLT2 
inhibitor)  as part of standard of care or as part of another investigational therapy is permitted.  
A10.4 Participants who become pregnant within 90 days of study treatment  
Sexually active women of childbearing potential must use highly effective form(s) of birth control 
(contraception) until the treatment with an SGLT2 inhibitor h as been completed. If a participant 
reports being pregnant during the 28 day treatment period the SGLT2 inhibitor will be permanently 
discontinued.  
 
A10.5 Duration of treatment  
 
Treatment with d apagliflozin (or empagliflozin/ another SGLT2 inhibitor)  will be continued through 
Day 28.  
A10.6 Discontinuation of study intervention  
 
At any time, patients are free to discontinue treatment or withdraw from the study, without prejudice 
to further treatment. A patient that decides to discontinue treatment will always be asked about the 
reason(s).  
 
Discontinuation from investigational product is not the same as complete withdrawal from the study.  
It is essential to collect data for all patients throughout the study. For that reason, a patient who 
discontinues tr eatment should optimally continue to follow up study assessments up to and 
including day of discharge (or Day 28). Alternatively, if the patient does not agree to this approach, 
modified follow -up should be arranged (eg, less frequent assessments, one cont act at Day 30, or 
other means). Patients who agree to some kind of modified follow up are still participating in the 
study.  
If a patient for some reason cannot be reached during the study, every attempt should be made to 
retrieve as much information regard ing this patient as possible. The site should continuously try to 
reach the patient, the patient’s family, or pre -identified contact person and search for information 
regarding the patient’s status in applicable sources to protect the validity of data. The se attempts 
should be documented.  
 
 
 A10.7 Study Schedule  
 
Activity  Screening/  
Enrollment  Hospital 
Duration  28 days or 
hospital 
discharge+ 
 90 days post 
randomization  
and long term 
follow -up++ 
Eligibility      
Consent  X    
Demographic and Medical History  X    
Assessment of Inclusion/Exclusion 
criteria  X    
Self-reported race/ethnicity and sex  X    
Pregnancy Test, for women of 
childbearing potential  X    
Study Drug Administration      
Randomization  X    
Study treatment  X X X  
Study Procedures      
Height  X    
Weight  X    
Vital signs  X X   
Concomitant medications  X X   
WHO ordinal assessment  X X X X 
Quality of Life and Functional Status# X   X 
Outcomes assessment   X X X 
SOC Laboratory Assessments      
Chemistry panel  X X X^  
CBC with platelet  count  X X X  
Blood Group*  X    
PT, PTT if known  X X   
D-dimer***  X X X  
Troponin****  X X X  
Coagulation and inflammatory 
markers*****  X X X  
Optional Biorepository  X X   
BNP or NT-proBNP  ***** X X  X  
 
^Chemistry panel (e.g. creatinine, acid-base) is strongly recommended to be measured at days 1,3,7,14, and 
at hospital discharge. M onitoring of acid -base balance in  patients with T2DM during hospitalization represents 
a standard of care in most institutions ; if there is a clinical concern f or DKA due to acid base status, this 
should be further investigated (see  A10.8.1).  
*Blood group taken from hospital record or self-report  if that is not available.  
** Frequency and mode (Anti -factor Xa/PTT) of testing will be based on site  routine. Anti -factor Xa monitoring 
is preferred over PTT  
*** Baseline D -dimer is recommended. All values collected should be recorded.  
****Strongly recommended as part of routine care, all values collected should be recorded  
*****Optional, listed in case report form  
 
 #Participants may be assessed for functional status and quality of life that reflects baseline status pre -COVID 
illness and functional status and quality of life at 90 days when contacted to ascertain vital status. 
(Instruments detailed in the manual of ope rations).  
+Assessments indicated in the table above will be ascertained at discharge or 28 days, whichever comes first. 
Participants must be followed for vital status until discharged from the hospital or another care facility (if 
transferred on organ sup port) for up to  90 days. To maximize retention, participants will be contacted 
intermittently post-discharge, and that contact will be recorded in the EDC . For participants  discharged prior to 
Day 28, this will include information about treatment adherenc e, to be collected as close to 30 days post -
randomization as possible.  
++Participants will be contacted to ascertain vital status.  
A10.8  Potential Risks & Benefits  
A10.8.1 Known and Potential Risks  
 The standard of care plus SGLT2 inhibitor  group may receive anticoagulants and/or antiplatelet  or 
additional antithrombotic therapies agents as part of standard care.  SGLT2 inhibitors are not known 
to have any impact on bleeding or thrombosis.  
 
The safety profiles of dapagliflozin (and empagliflo zin) are already well established from prior 
clinical studies in various clinical settings. These studies have demonstrated that SGLT2 inhibitors 
are generally safe and well tolerated.  
 
Dapagliflozin and empagliflozin, as inhibitors of SGLT2, increase urin ary glucose excretion, which is 
commonly believed to increase the risk of urinary tract infections. Urinary tract infections have been 
reported in dapagliflozin -treated patients in a slightly higher proportion than in placebo -treated 
patients in some globa l Phase III studies, although the rates of urinary tract infections (and serious 
urinary tract infections) observed in large clinical trials of dapagliflozin and other SGLT2i have been 
similar to placebo (16, 2). Increased urinary glucose excretion may als o lead to an increased risk of 
developing genital infections. Genital infections are considered common side effects (in ≥1/100 to 
<1/10 patients), but the risk of these events is considered to be low due to the brief duration of 
treatment planned in this t rial. 
 
Dapagliflozin and empagliflozin modestly reduce blood pressure and may reduce blood volume 
from their diuretic effects, which could be a potential concern in patients with Covid -19. A pooled 
analysis of patients with T2DM and HF in the dapagliflozin  development program, showed no 
increase of volume depletion events (17). In DARE -19 trial, there was no indication of increased risk 
for volume depletion and the number of acute kidney injury events was lower with dapagliflozin as 
compared with placebo.  
 
Neither dapagliflozin nor empagliflozin have been shown to induce hypoglycemia in non -diabetic 
patients. In clinical pharmacology studies of dapagliflozin, healthy subjects have been treated with 
single oral doses of up to 500 mg and multiple oral doses of  100 mg up to 14 days without any 
hypoglycemic events. However, in patients with T2DM and on insulin or sulfonylurea medication, 
there is an increased risk of hypoglycemia. Patients with T2DM will be monitored in the hospital as 
part of standard of care, w hich includes blood glucose monitoring.  
 
There have been reports of ketoacidosis, including DKA, in patients with T2DM taking dapagliflozin 
and other SGLT2 inhibitors. Diabetic ketoacidosis (which may occur without substantial elevation of 
blood glucose va lues – i.e. euglycemic diabetic ketoacidosis) is considered a rare (in ≥1/10000 to 
<1/1000 patients) adverse drug reaction for dapagliflozin in patients with T2DM (15). Patients 
treated with dapagliflozin who present with signs and symptoms consistent with  ketoacidosis, 
including nausea, vomiting, abdominal pain, malaise, and shortness of breath, should be assessed 
 
 for ketoacidosis, even if blood glucose levels are below 14 mmol/L (250 mg/dL). If ketoacidosis is 
suspected, interruption of dapagliflozin (and  other SGLT2 inhibitor) therapy should be considered, 
and the patient should be evaluated promptly. Predisposing factors to ketoacidosis include a low 
beta-cell function reserve resulting from pancreatic disorders (eg, type 1 diabetes, history of 
pancreati tis, or pancreatic surgery), insulin dose reduction, reduced caloric intake, or increased 
insulin requirements caused by infections, illness or surgery and alcohol use.  
 
In DARE -19 trial, only two cases of DKA were reported in patients treated with dapagl iflozin (versus 
0 with placebo), both in patients with Type 2 diabetes; both were non -severe, and resolved quickly 
after discontinuation of study medication.  
  
Appropriate measures are in place to monitor and minimize potential risks to participating patie nts, 
including the use of an DSMB that will continuously evaluate safety data. Patients with type 1 
diabetes mellitus and patients with a history of DKA are excluded from this study. Monitoring of 
acid-base balance in patients with T2DM during hospitalizat ion represents a standard of care in 
most institutions. Should there be an abnormal increase in anion gap and/or reduced bicarbonate 
levels, measurement of blood levels of ketones, lactate, and analysis of pH should be performed, 
and treatment with SGLT2 i nhibitors should be temporarily discontinued, if DKA is suspected.  
 
A diagnosis of DKA should only be made in a clinical setting consistent with DKA (based on patient 
history, symptoms, and physical exam) and in the absence of more likely alternative diag noses and 
causes of acidosis (such as lactic acidosis). The following biochemical data should support 
diagnosis:  
 
• Ketonemia ≥3.0 mmol/L and/or significant ketonuria (more than 2+ on standard urine sticks) 
in the absence of elevated lactate (lactate shoul d be <2 mmol/L to be considered a potential DKA)  
and 
• At least one of the following criteria suggesting high anion gap metabolic acidosis:  
(a) Arterial or Venous pH ≤7.3  
(b) Serum bicarbonate ≤18 mEq/L  
(c) Anion gap [Na – (Cl + HCO3)] >10  
 
If a diagnosis of DKA is confirmed, treatment with SGLT2 inhibitors should be permanently 
discontinued.  
A10.8.2 Known Potential Benefits  
 
Preliminary data from DARE -19 trial strongly suggest that use of SGLT2 inhibitors in patients 
hospitalized with Covid -19 may reduce the risk of organ failure or death from any cause via a 
number of pathophysiologic pathways, including favorable effects on endothelial function, oxidative 
stress, inflammation, oxygen -carrying capacity and tissue hypoxia, as well as through inhibition of 
glycolysis and lipogenesis.  
 
This arm seeks to test the hypothesis that the SGLT2  inhibitor s dapagliflozin or empagliflozin , on 
top of standard of care therapy, would decrease adverse events, including death  and organ support 
free days. This trial will con tribute to the body of generalizable knowledge about SGLT2 inhibitor  
therapy and the role of organ protection through SGLT2 inhibition  in Covid-19 disease to minimize 
the risk of adverse events in patients hospitalized with C ovid-19.   
 
 
 All patients in the  study are expected to be treated optimally according to background local 
standard of care therapy, including treatments to control co -morbidities. SGLT2 inhibitors 
dapagliflozin or empagliflozin will be administered in addition to these treatments.  
These patients are hospitalized and will receive close medical attention, irrespective of treatment 
allocation.  
A10.9Event Adjudication  
A subset of thrombotic events will be centrally adjudicated, with the proportion adjusted as needed 
based on agreement between  the site and the event committee.  
A10.10 Safety Analyses  
The rate of SAEs  (including DKA) will be monitored. The DSMB will review the number of events, 
the event rates, and the posterior mean and 95% credible intervals for the event rates, difference 
between arms, and odds -ratios between arms will be summarized.  
 
A10.11 Statistical Analyses  
This arm will be compared to the SGLT2 inhibitor  standard of care arm.  Patients eligible for SGLT2 
inhibitor will be randomized to either an SGLT2 inhibitor or no SGLT2 inhibitor .  These same 
patients may be randomized to other therapies within this master protocol.  The comparison will be 
between those randomized to SGLT2 inhibitor vs those randomized to no SGLT2 inhibitor .   
 
The primary Bayesian statistical model  (see Statistical Analysis Plan ) will be used for modeling th e 
effect of SGLT2 inhibitor in comparison  to no SGLT2 inhibitor with the following exceptions:  
1. The model will contain a main effect for each other therapy that was randomized for each 
patient.  
2. Site will not be included in the primary analysis model, but instead the country for the site 
will be included.  
 
The Statistical Analysis Plan presents the interim analysis schedule and adaptive decision rules.  
 
The primary analysis for SGLT2 inhibitor will be restricted to only patients in the intent -to-treat for 
SGLT2 inhibitor .  This group are those patients that have been randomized to potentially receive an 
SGLT2 inhibitor .  No patients that were not randomized to yes/no for SGLT2 inhibitor will be used in 
the primary analysis for SGLT2 inhibitor .  
 
A10.12 Safety Reporting  
Safety reporting will be the same as outlined in the Master Protocol. In addition, serious adverse 
events of DKA will be collected.  
A10.13 References  
 
1. Zinman B, Wanner C, Lachin  JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, 
Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA -REG OUTCOME 
Investigators.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.  
N Engl J Med. 2015 Nov 26;373(22):2117 -28. doi: 10.1056/NEJMoa1504720. Epub 2015 
Sep 17  
2. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, 
Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de 
 
 Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, 
Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, 
Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, 
Sjöstrand M, Langkilde AM; DAPA -HF Trial Committees and Investiga tors. Dapagliflozin in 
Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 
21;381(21):1995 -2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.  
3. Heerspink HJL, Stefánsson BV, Correa -Rotter R, Chertow GM, Greene T, Hou FF, Mann 
JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, 
Wheeler DC; DAPA -CKD Trial Committees and Investigators. Dapagliflozin in Patients with 
Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436 -1446. doi: 
10.1056/NEJMoa2024 816. Epub 2020 Sep 24.  
4. Daniele G, Xiong J, Solis -Herrera C, et al. Dapagliflozin Enhances Fat Oxidation and Ketone 
Production in Patients With Type 2 Diabetes. Diabetes Care  2016; 39: 2036 -41. doi 
10.2337/dc15 -2688  
5. Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial 
dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a 
pilot study. Cardiovasc Diabetol  2017; 16: 138. doi 10.1186/s12933 -017-0621 -8 
6. Bonnet F, Scheen AJ. Effects of SGLT2 in hibitors on systemic and tissue low -grade 
inflammation: The potential contribution to diabetes complications and cardiovascular 
disease. Diabetes Metab  2018; 44: 457 -64. doi 10.1016/j.diabet.2018.09.005  
7. Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modul ates NLRP3 inflammasome activity 
via ketones and insulin in diabetes with cardiovascular disease. Nat Commun  2020; 11: 
2127. doi 10.1038/s41467 -020-15983 -6 
8. Maayah ZH, Ferdaoussi M, Takahara S, Soni S, Dyck JRB. Empagliflozin  suppresses 
inflammation and protects against acute septic renal injury. Inflammopharmacology  2021; 
29: 269 -79. doi 10.1007/s10787 -020-00732 -4 
9. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose -
regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes 
Metab  2013; 15: 853 -62. doi 10.1111/dom.12127  
10. Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin Suppresses Hepcidin And Increases 
Erythropoiesis. J Clin Endocrinol Metab  2020; 105: e1056 -e63. do i 10.1210/clinem/dgaa057  
11. Ohara K, Masuda T, Morinari M, et al. The extracellular volume status predicts body fluid 
response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr  
2020; 12: 37. doi 10.1186/s13098 -020-00545 -z 
12.  Heer spink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray 
JJV, Rossing P, Correa -Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde 
AM, Wheeler DC; DAPA -CKD Trial Committees and Investigators. Effects of dapagliflozin 
on mortalit y in patients with chronic kidney disease: a pre -specified analysis from the 
DAPA -CKD randomized controlled trial. Eur Heart J. 2021 Mar 31;42(13):1216 -1227. doi: 
10.1093/eurheartj/ehab094.  
13. Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, Ka r P, Meace C, Sattar 
N, Sharp S, Wareham NJ, Weaver A, Woch E, Young B, Valabhji J. Prescription of 
glucose -lowering therapies and risk of COVID -19 mortality in people with type 2 diabetes: a 
nationwide observational study in England. Lancet Diabetes Endoc rinol. 2021 
May;9(5):293 -303. doi: 10.1016/S2213 -8587(21)00050 -4. Epub 2021  
14. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, 
Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, 
Tang F, Gosch K, Windso r SL, Akin EE, Soares RVP, Moia DDF, Aboudara M, Hoffmann 
Filho CR, Feitosa ADM, Fonseca A, Garla V, Gordon RA, Javaheri A, Jaeger CP, Leaes 
PE, Nassif M, Pursley M, Silveira FS, Barroso WKS, Lazcano Soto JR, Nigro Maia L, 
Berwanger O. Dapagliflozin in pat ients with cardiometabolic risk factors hospitalised with 
 
 COVID -19 (DARE -19): a randomised, double -blind, placebo -controlled, phase 3 trial. 
Lancet Diabetes Endocrinol 2021 Jul 21;S2213 -8587(21)00180 -7. doi: 10.1016/S2213 -
8587(21)00180 -7. Online ahead of p rint. 
15. Rajeev SP, Wilding JPH. SGLT2 inhibition and ketoacidosis – should we be concerned? Br 
J Diabetes Vasc Dis 2015;15:155 -158. http://dx.doi.org/10.15277/bjdvd.2015.047  
16. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker  TA, 
Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause -
Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE –TIMI 
58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J 
Med. 2019 Jan 24;380(4):347 -357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.  
17. Kosiborod M, Gause -Nilsson I, Xu J, Sonesson C, Johnsson E.J. Efficacy and safety of 
dapagliflozin in patients with type 2 diabetes and concomitant heart failure. Diabetes 
Complications. 2017 Jul;31(7):1215 -1221. doi: 10.1016/j.jdiacomp.2017.02.001. Epub 2017 
Feb 
 
 
 